{"id":2772,"date":"2017-09-23T06:49:58","date_gmt":"2017-09-23T04:49:58","guid":{"rendered":"https:\/\/eae.gr\/uncategorized\/pollaplo-myeloma\/"},"modified":"2024-07-27T00:27:58","modified_gmt":"2024-07-26T22:27:58","slug":"pollaplo-myeloma","status":"publish","type":"post","link":"https:\/\/eae.gr\/en\/active-clinical-studies-en\/pollaplo-myeloma\/","title":{"rendered":"\u03a0\u039f\u039b\u039b\u0391\u03a0\u039b\u039f  \u039c\u03a5\u0395\u039b\u03a9\u039c\u0391"},"content":{"rendered":"<p><strong>\u039d\u0395\u039f\u0394\u0399\u0391\u0393\u039d\u03a9\u03a3\u0398\u0395\u039d\u03a4\u0395\u03a3 \u0391\u03a3\u0398\u0395\u039d\u0395\u0399\u03a3 \u039c\u0395 \u03a0\u039f\u039b\u039b\u0391\u03a0\u039b\u039f \u039c\u03a5\u0395\u039b\u03a9\u039c\u0391<\/strong><\/p>\n<p><strong>EMN33-TAURUS Transplant eligible DARAVRD induction-ASCT-2 <\/strong><strong>\u039a\u03cd\u03ba\u03bb\u03bf\u03b9<\/strong><strong> DARAVRD consolidation<\/strong><\/p>\n<ul>\n<li>\u039d\u03ad\u03b1 \u03b4\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7 \u03bc\u03b5 \u03c3\u03c5\u03bc\u03c0\u03c4\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03cc \u03c0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03cc \u03bc\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1<\/li>\n<li>eGFR &gt; 30ml\/min<\/li>\n<li>Mpeak &gt; 0.5 g\/dL, Upeak &gt;200 mg\/24h, \u03bb\u03cc\u03b3\u03bf\u03c2 \u03b5\u03bb\u03b1\u03c6\u03c1\u03ce\u03bd \u03b1\u03bb\u03cd\u03c3\u03b5\u03c9\u03bd &gt; 100<\/li>\n<\/ul>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u03b5\u03bd\u03b9\u03ba\u03cc \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf \u0391\u03b8\u03b7\u03bd\u03ce\u03bd &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u0395.\u03a4\u03ad\u03c1\u03c0\u03bf\u03c2<br \/>\n\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<br \/>\n\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0386\u03b3\u03b9\u03bf\u03c2 \u03a3\u03b1\u03b2\u03b2\u03b1\u03c2&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0391. \u03a0\u03bf\u03c5\u03bb\u03ae<br \/>\n\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u0393\u039d \u0391\u03bb\u03b5\u03be\u03b1\u03bd\u03b4\u03c1\u03bf\u03cd\u03c0\u03bf\u03bb\u03b7\u03c2, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395. \u03a3\u03c0\u03b1\u03bd\u03bf\u03c5\u03b4\u03ac\u03ba\u03b7\u03c2<\/li>\n<\/ul>\n<hr \/>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>C1071006\/ MAGNETISMM-6 <\/strong><strong>\u03c4\u03c5\u03c7\u03b1\u03b9\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03b7<\/strong><strong>, <\/strong><strong>\u03c6\u03ac\u03c3\u03b7\u03c2<\/strong><strong> 3, Elra-DaraRd vs DaraRd <\/strong><strong>\u03c3\u03b5<\/strong><strong> non-transplant eligible (RRMM <\/strong><strong>\u03bc\u03cc\u03bd\u03bf<\/strong><strong> part 1) hold <\/strong><strong>\u03c0\u03c1\u03bf\u03c3\u03c9\u03c1\u03b9\u03bd\u03ac<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>1)\u0394\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7 \u03a0\u039c \u03ba\u03b1\u03c4\u03ac IMWG \u03ba\u03b1\u03b9 \u03bc\u03b5\u03c4\u03c1\u03ae\u03c3\u03b9\u03bc\u03b7 \u03bd\u03cc\u03c3\u03bf\u03c2:<br \/>\n\u2022 \u03a0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u039c \u03bf\u03c1\u03bf\u03cd \u22650,5 g\/dL \u03ae\/\u03ba\u03b1\u03b9 \u03a0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2 \u039c \u03c3\u03c4\u03b1 \u03bf\u03cd\u03c1\u03b1 \u2265200 mg\/24\u03c9\u03c1\u03bf,<br \/>\n\u2022 \u0395\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03b7 \u03b5\u03bb\u03b5\u03cd\u03b8\u03b5\u03c1\u03b7 \u03b5\u03bb\u03b1\u03c6\u03c1\u03b9\u03ac \u03b1\u03bb\u03c5\u03c3\u03af\u03b4\u03b1 (FLC) \u226510 mg\/dL (\u2265100 mg\/L) \u039a\u0391\u0399 \u03bc\u03b7 \u03c6\u03c5\u03c3\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc\u03c2 \u03bb\u03cc\u03b3\u03bf\u03c2 \u03ba\u03ac\u03c0\u03b1 \u03c0\u03c1\u03bf\u03c2 \u03bb\u03ac\u03bc\u03b4\u03b1 FLC\u03b1\u03bd\u03bf\u03c3\u03bf\u03c3\u03c6\u03b1\u03b9\u03c1\u03b9\u03bd\u03ce\u03bd \u03bf\u03c1\u03bf\u03cd (1,65)<br \/>\n2)\u039c\u03ad\u03c1\u03bf\u03c2 1 \u03bc\u03cc\u03bd\u03bf: \u03a3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03c9\u03bd \u03bc\u03b5 NDMM \u03ae RRMM.<br \/>\n\u2022 \u039f \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03c9\u03bd \u03bc\u03b5 NDMM \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03ba\u03b1\u03c4\u03ac\u03bb\u03bb\u03b7\u03bb\u03bf\u03c2 \u03b3\u03b9\u03b1 \u03bc\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7, \u03cc\u03c0\u03c9\u03c2 \u03bf\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03b7\u03bb\u03b9\u03ba\u03af\u03b1 \u226565 \u03b5\u03c4\u03ce\u03bd, \u03ae \u03b1\u03ba\u03b1\u03c4\u03ac\u03bb\u03bb\u03b7\u03bb\u03bf\u03c2 \u03b3\u03b9\u03b1 \u03bc\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7, \u03cc\u03c0\u03c9\u03c2 \u03bf\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03b7\u03bb\u03b9\u03ba\u03af\u03b1 \uf03c65 \u03b5\u03c4\u03ce\u03bd \u03bc\u03b5 \u03c3\u03c5\u03bd\u03bd\u03bf\u03c3\u03b7\u03c1\u03cc\u03c4\u03b7\u03c4\u03b5\u03c2 \u03c0\u03bf\u03c5 \u03b5\u03c0\u03b7\u03c1\u03b5\u03ac\u03b6\u03bf\u03c5\u03bd \u03c4\u03b7\u03bd \u03c0\u03b9\u03b8\u03b1\u03bd\u03cc\u03c4\u03b7\u03c4\u03b1 \u03bc\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7\u03c2.<br \/>\n\u2022 \u039f\u03b9 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03bf\u03bd\u03c4\u03b5\u03c2 \u03bc\u03b5 RRMM \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 1-2 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03b3\u03b9\u03b1 \u03c4\u03bf \u03a0\u039c, \u03c3\u03c5\u03bc\u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03b1\u03bd\u03bf\u03bc\u03ad\u03bd\u03bf\u03c5 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd \u03b5\u03bd\u03cc\u03c2 IMiD \u03ba\u03b1\u03b9 \u03b5\u03bd\u03cc\u03c2 PI.<br \/>\n\u2022 \u039c\u03ad\u03c1\u03bf\u03c2 2: NDMM non-transplant eligible<br \/>\n\u2022 ECOG \u22642.<br \/>\n\u2022 \u03b1. ANC \u22651,0 \u00d7 109 \/L, \u03b2. \u0391\u03c1\u03b9\u03b8\u03bc\u03cc\u03c2 \u03b1\u03b9\u03bc\u03bf\u03c0\u03b5\u03c4\u03b1\u03bb\u03af\u03c9\u03bd \u226575.000\/\u03bcL, \u03b3. \u0391\u03b9\u03bc\u03bf\u03c3\u03c6\u03b1\u03b9\u03c1\u03af\u03bd\u03b7 \u22658 g\/dL<br \/>\n\u2022 \u0394\u03b9\u03bf\u03c1\u03b8\u03c9\u03bc\u03ad\u03bd\u03bf \u03b1\u03c3\u03b2\u03ad\u03c3\u03c4\u03b9\u03bf \u03bf\u03c1\u03bf\u03cd \u226414 mg\/dL (\u22643,5 mmol\/L) \u03ae \u03b5\u03bb\u03b5\u03cd\u03b8\u03b5\u03c1\u03bf \u03b9\u03bf\u03bd\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b1\u03c3\u03b2\u03ad\u03c3\u03c4\u03b9\u03bf \u22646,5 mg\/dL (\u22641,6 mmol\/L).<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 \u03a3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03c0\u03b1\u03c1\u03b1\u03c4\u03b5\u03c4\u03b1\u03bc\u03ad\u03bd\u03bf\u03c5 QT (\u03ae QTcF&gt;470 msec \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7 \u03b4\u03b9\u03b1\u03bb\u03bf\u03b3\u03ae).<br \/>\n\u2022 LVEF \uf03c40%<br \/>\n\u2022 \u03b5\u03bd\u03b5\u03c1\u03b3\u03cc\u03c2 \u03bb\u03bf\u03af\u03bc\u03c9\u03be\u03b7 HBV,HCV, HIV<br \/>\n\u2022 \u0395\u03bd\u03b5\u03c1\u03b3\u03ae \u03c6\u03bb\u03b5\u03b3\u03bc\u03bf\u03bd\u03ce\u03b4\u03b7\u03c2 \u03b3\u03b1\u03c3\u03c4\u03c1\u03b5\u03bd\u03c4\u03b5\u03c1\u03b9\u03ba\u03ae \u03bd\u03cc\u03c3\u03bf\u03c2 \u03ba\u03b1\u03b9 \u03b5\u03ba\u03ba\u03bf\u03bb\u03c0\u03ce\u03bc\u03b1\u03c4\u03b1<br \/>\n\u039c\u03ad\u03c1\u03bf\u03c2 1 \u03bc\u03cc\u03bd\u03bf:<br \/>\n\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03ba\u03b1\u03c4\u03b5\u03c5\u03b8\u03c5\u03bd\u03cc\u03bc\u03b5\u03bd\u03b7 \u03c0\u03c1\u03bf\u03c2 \u03c4\u03bf BCMA, \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03ba\u03b1\u03c4\u03b5\u03c5\u03b8\u03c5\u03bd\u03cc\u03bc\u03b5\u03bd\u03b7 \u03c0\u03c1\u03bf\u03c2 \u03c4\u03bf \u03b1\u03bd\u03c4\u03b9-CD38 \u03b5\u03bd\u03c4\u03cc\u03c2 6 \u03bc\u03b7\u03bd\u03ce\u03bd \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03c0\u03c1\u03ce\u03c4\u03b7 \u03b4\u03cc\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03c0\u03b1\u03c1\u03ad\u03bc\u03b2\u03b1\u03c3\u03b7\u03c2 \u03c4\u03b7\u03c2 \u03bc\u03b5\u03bb\u03ad\u03c4\u03b7\u03c2 \u03c3\u03b5 \u03b1\u03c5\u03c4\u03ae\u03bd \u03c4\u03b7 \u03bc\u03b5\u03bb\u03ad\u03c4\u03b7 \u03ae \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03ae \u03c3\u03b5 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03ba\u03b1\u03c4\u03b5\u03c5\u03b8\u03c5\u03bd\u03cc\u03bc\u03b5\u03bd\u03b7 \u03c0\u03c1\u03bf\u03c2 \u03c4\u03bf \u03b1\u03bd\u03c4\u03b9-CD38.<br \/>\n\u2022 \u03a0\u03c1\u03c9\u03c4\u03bf\u03c0\u03b1\u03b8\u03ad\u03c2 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc \u03a0\u039c<br \/>\n\u2022 \u039c\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7 \u22643 \u03bc\u03ae\u03bd\u03b5\u03c2<br \/>\n\u2022 \u03a7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7 \u03c5\u03c0\u03cc \u03ad\u03c1\u03b5\u03c5\u03bd\u03b1 \u03c0\u03c1\u03bf\u03ca\u03cc\u03bd\u03c4\u03bf\u03c2 \u03c4\u03b1\u03c5\u03c4\u03cc\u03c7\u03c1\u03bf\u03bd\u03b1 \u03ae \u03b5\u03bd\u03c4\u03cc\u03c2 30 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03c0\u03c1\u03ce\u03c4\u03b7 \u03b4\u03cc\u03c3\u03b7<br \/>\n\u2022 \u039f\u03bb\u03b9\u03ba\u03ae \u03c7\u03bf\u03bb\u03b5\u03c1\u03c5\u03b8\u03c1\u03af\u03bd\u03b7&gt;1,5 \u00d7 ULN (&gt;3 \u00d7 ULN \u03b5\u03ac\u03bd \u03ad\u03c7\u03b5\u03b9 \u03c4\u03b5\u03ba\u03bc\u03b7\u03c1\u03b9\u03c9\u03b8\u03b5\u03af \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf Gilbert),<br \/>\n\u2022 AST &gt;2,5 \u00d7 ULN \u03ba\u03b1\u03b9 ALT &gt;2,5 \u00d7 ULN.<br \/>\n\u2022 \u039c\u03ad\u03c1\u03bf\u03c2 1: EGFR&lt;60 mL\/min\/1,73 m2<br \/>\n\u2022 \u039c\u03ad\u03c1\u03bf\u03c2 2: EGFR&lt;30 mL\/min\/1,73 m2<\/p>\n<p><strong>\u00a0\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><strong>:<\/strong><\/p>\n<ul>\n<li>\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d \u0391\u03b8\u03b7\u03bd\u03ce\u03bd &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<\/li>\n<li>\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u03b1\u03bd\u03b5\u03c0\u03b9\u03c3\u03c4\u03b7\u03bc\u03b9\u03b1\u03ba\u03cc \u0399\u03c9\u03b1\u03bd\u03bd\u03af\u03bd\u03c9\u03bd, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395. \u03a7\u03b1\u03c4\u03b6\u03b7\u03bc\u03b9\u03c7\u03b1\u03ae\u03bb<\/li>\n<li><span style=\"color: #ff0000;\">\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221; \u0398\u03b5\u03c3\u03c3\u03b1\u03bb\u03bf\u03bd\u03af\u03ba\u03b7 -\u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5 (not active yet)<\/span><\/li>\n<li>\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<\/li>\n<\/ul>\n<hr \/>\n<p><strong>DaraBelaRd<\/strong> <strong>[sc daratumumab, lenalidomide, dexamethasone, belamaf every 8 weeks 1,9mg\/kg 1,4 mg\/kg] \u039f\u03bb\u03bf\u03ba\u03bb\u03b7\u03c1\u03ce\u03b8\u03b7\u03ba\u03b5 \u03c4\u03bf part 1 \u03b5\u03bd \u03b1\u03bd\u03b1\u03bc\u03bf\u03bd\u03ae \u03c4\u03bf\u03c5 part 2<\/strong><\/p>\n<p>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/p>\n<p>\u2022 \u03a0\u039c \u03ba\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 CRAB or myeloma-defining events, ASCT non-eligible, ECOG 0-2<br \/>\n\u2022 Mpeak&gt; 0.5 g\/dl, Upeak&gt; 200mg\/24h, \u03b5\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03b7 FLC &gt; 100mg\/L \u03ba\u03b1\u03b9\u03c0\u03b1\u03b8\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc ratio<br \/>\n\u2022 ANC &gt; 1250, Hb &gt;8g\/dl, PLTs &gt; 50.000<br \/>\n\u2022 eGFR&gt; 30mL\/min\/1.73m2 , ALT&lt; 2.5ULN, t.bil&lt;1.5 ULN<\/p>\n<p>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/p>\n<p>\u2022 \u039d\u03b5\u03c5\u03c1\u03bf\u03c0\u03ac\u03b8\u03b5\u03b9\u03b1 gr 2 \u03ae \u03bc\u03b5\u03b3\u03b1\u03bb\u03cd\u03c4\u03b5\u03c1\u03bf<br \/>\n\u2022 \u0391\u03bd \u03a7\u0391\u03a0 \u03c3\u03c0\u03b9\u03c1\u03bf\u03bc\u03ad\u03c4\u03c1\u03b7\u03c3\u03b7<br \/>\n\u2022 HbsAg \u03b8\u03b5\u03c4\u03b9\u03ba\u03cc , HCV<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u03b5\u03bd\u03b9\u03ba\u03cc \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf \u0391\u03b8\u03b7\u03bd\u03ce\u03bd &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u0395.\u03a4\u03ad\u03c1\u03c0\u03bf\u03c2<\/li>\n<li>\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<\/li>\n<\/ul>\n<hr \/>\n<p><strong>EAE128: BelaRd+Niro: \u03c6\u03ac\u03c3\u03b7\u03c2 1\/2, \u03b1\u03bd\u03bf\u03b9\u03c7\u03c4\u03ae \u03bc\u03b5\u03bb\u03ad\u03c4\u03b7 \u03b3\u03b9\u03b1 \u03c4\u03b7\u03bd \u03b1\u03be\u03b9\u03bf\u03bb\u03cc\u03b3\u03b7\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03b1\u03c3\u03c6\u03ac\u03bb\u03b5\u03b9\u03b1\u03c2 \u03ba\u03b1\u03b9 \u03c4\u03b7\u03c2 \u03ba\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae\u03c2 \u03b4\u03c1\u03b1\u03c3\u03c4\u03b7\u03c1\u03b9\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2 \u03b4\u03b9\u03b1\u03c6\u03bf\u03c1\u03b5\u03c4\u03b9\u03ba\u03ce\u03bd \u03b4\u03cc\u03c3\u03b5\u03c9\u03bd \u03bc\u03c0\u03b5\u03bb\u03b1\u03bd\u03c4\u03b1\u03bc\u03ac\u03bc\u03c0\u03b7\u03c2\u03bc\u03b1\u03c6\u03bf\u03b4\u03bf\u03c4\u03af\u03bd\u03b7\u03c2 \u03c3\u03b5 \u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc \u03bc\u03b5 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7, \u03b4\u03b5\u03be\u03b1\u03bc\u03b5\u03b8\u03b1\u03b6\u03cc\u03bd\u03b7 \u03ba\u03b1\u03b9 \u03bd\u03b9\u03c1\u03bf\u03b3\u03ba\u03b1\u03c3\u03b5\u03c3\u03c4\u03ac\u03c4\u03b7. 1,4 mg\/kg<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<br \/>\n<\/strong>\u2022 \u03a0\u039c \u03ba\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 CRAB or myeloma-defining events, ASCT non-eligible, ECOG 0-2<br \/>\n\u2022 Mpeak&gt; 0.5 g\/dl, Upeak&gt; 200mg\/24h, \u03b5\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03b7 FLC &gt; 100mg\/L \u03ba\u03b1\u03b9 \u03c0\u03b1\u03b8\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc ratio<br \/>\n\u2022 ANC &gt; 1250, Hb &gt;8g\/dl, PLTs &gt; 50.000<br \/>\n\u2022 eGFR &gt; 30mL\/min\/1.73m2 , ALT &lt; 2.5ULN, t.bil&lt;1.5 ULN<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<ul>\n<li>\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u03b5\u03bd\u03b9\u03ba\u03cc \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf \u0391\u03b8\u03b7\u03bd\u03ce\u03bd &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u0395.\u03a4\u03ad\u03c1\u03c0\u03bf\u03c2<\/li>\n<\/ul>\n<hr \/>\n<p><strong>AGMT MM4 \u2013 ISARd vs Rd<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 \u0397\u03bb\u03b9\u03ba\u03af\u03b1 \u2265 70 \u03b5\u03c4\u03ce\u03bd<br \/>\n\u2022 \u03a0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u039c \u03bf\u03c1\u03bf\u03cd \u22650,5 g\/dL\u03ba\u03b1\u03b9\/\u03ae\u039c \u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u03bf\u03cd\u03c1\u03c9\u03bd \u2265200 mg\/24 \u03ce\u03c1\u03b5\u03c2 \u03ba\u03b1\u03b9\/\u03ae\u03b5\u03bb\u03b5\u03cd\u03b8\u03b5\u03c1\u03b7\u03b5\u03bb\u03b1\u03c6\u03c1\u03ac\u03b1\u03bb\u03c5\u03c3\u03af\u03b4\u03b1 \u03bf\u03c1\u03bf\u03cd (SFLC) \u2265 100 mg\/L (\u03b5\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03b7 \u03b5\u03bb\u03b1\u03c6\u03c1\u03ac \u03b1\u03bb\u03c5\u03c3\u03af\u03b4\u03b1) \u03ba\u03b1\u03b9 \u03bc\u03b7\u03c6\u03c5\u03c3\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03b1\u03bd\u03b1\u03bb\u03bf\u03b3\u03af\u03b1 FLC<br \/>\n\u2022 ECOGPS 0-2, LVEF \u03b5\u03af\u03bd\u03b1\u03b9 &gt;40%<br \/>\n\u2022 \u03a7\u03bf\u03bb\u03b5\u03c1\u03c5\u03b8\u03c1\u03af\u03bd\u03b7&lt; x2ULN, AST \u03ba\u03b1\u03b9 ALT&lt; 3 \u03c6\u03bf\u03c1\u03ad\u03c2 \u03c4\u03bfULN<br \/>\n\u2022 ANC \u2265 750\/mm3<br \/>\n\u2022 \u0391\u03b9\u03bc\u03bf\u03c3\u03c6\u03b1\u03b9\u03c1\u03af\u03bd\u03b7 &gt; 8,0 g\/dL<br \/>\n\u2022 \u0391\u03b9\u03bc\u03bf\u03c0\u03b5\u03c4\u03ac\u03bb\u03b9\u03b1&gt;50.000\/mm3<br \/>\n\u2022 CrCl \u226530 mL\/minMDRD<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 PCL, MGUS, sMM<br \/>\n\u2022 \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03b3\u03bb\u03c5\u03ba\u03bf\u03ba\u03bf\u03c1\u03c4\u03b9\u03ba\u03bf\u03b5\u03b9\u03b4\u03ae \u03b5\u03bd\u03c4\u03cc\u03c2 14 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03c4\u03c5\u03c7\u03b1\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u03c0\u03bf\u03c5 \u03c5\u03c0\u03b5\u03c1\u03b2\u03b1\u03af\u03bd\u03b5\u03b9 \u03c4\u03b7 \u03c3\u03c5\u03c3\u03c3\u03c9\u03c1\u03b5\u03c5\u03bc\u03ad\u03bd\u03b7 \u03b4\u03cc\u03c3\u03b7 \u03c4\u03c9\u03bd 160 mg\u03b4\u03b5\u03be\u03b1\u03bc\u03b5\u03b8\u03b1\u03b6\u03cc\u03bd\u03b7\u03c2 \u03ae \u03c4\u03c9\u03bd 1000 mg\u03c0\u03c1\u03b5\u03b4\u03bd\u03b9\u03b6\u03cc\u03bd\u03b7\u03c2<br \/>\n\u2022 HIV, HBV, HCV<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<ul>\n<li>\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u03b5\u03bd\u03b9\u03ba\u03cc \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf \u0391\u03b8\u03b7\u03bd\u03ce\u03bd &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u0395.\u03a4\u03ad\u03c1\u03c0\u03bf\u03c2<\/li>\n<li>\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<\/li>\n<\/ul>\n<hr \/>\n<p><strong>\u0395\u0391\u0395 116 \u2013 ISAVCD \u03c3\u03b5 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 \u03bd\u03ad\u03b1 \u03b4\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7 \u03a0\u039c \u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1\u00a0<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 e-GFR&lt;30ml\/min\/1,73m2(CKD-EPI)<br \/>\n\u2022 ECOGPS\u22642<br \/>\n\u2022 SPEP&gt; 0,5g\/dL, \u03ba\u03b1\u03b9\/\u03ae<br \/>\n\u2022 Upeak\u2265200mg\/24\u03c9\u03c1\u03ce\u03bd,<br \/>\n\u2022 FLC \u226510mg\/ \u03ba\u03b1\u03b9 \u03c0\u03b1\u03b8\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc ratio<br \/>\n\u2022 ANC\u22651,0 x109\/L<br \/>\n\u2022 Hb\u22657,5g\/dL<br \/>\n\u2022 PLTs\u226575 x109\/L<br \/>\n\u2022 ALT, AST \u22642,5X ULN<br \/>\n\u2022 Totalbil\u22641,5ULN<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 HAV, HBV, HCV, HIV<br \/>\n\u2022 \u0395\u03bc\u03b2\u03cc\u03bb\u03b9\u03bf \u03bc\u03b5 \u03b6\u03ce\u03bd\u03c4\u03b1 \u03b5\u03be\u03b1\u03c3\u03b8\u03b5\u03bd\u03b7\u03bc\u03ad\u03bd\u03bf \u03c3\u03c4\u03ad\u03bb\u03b5\u03c7\u03bf\u03c2 \u03b5\u03bd\u03c4\u03cc\u03c2 4 \u03b5\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03c9\u03bd \u03b1\u03c0\u03cc C1d1<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u03b5\u03bd\u03b9\u03ba\u03cc \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf \u0391\u03b8\u03b7\u03bd\u03ce\u03bd &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u0395.\u03a4\u03ad\u03c1\u03c0\u03bf\u03c2<br \/>\n\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d \u0391\u03b8\u03b7\u03bd\u03ce\u03bd &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<br \/>\n\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u0393\u039d \u03a0\u03b1\u03c4\u03c1\u03ce\u03bd<br \/>\n\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u03b1\u03bd\u03b5\u03c0\u03b9\u03c3\u03c4\u03b7\u03bc\u03b9\u03b1\u03ba\u03cc \u0399\u03c9\u03b1\u03bd\u03bd\u03af\u03bd\u03c9\u03bd<br \/>\n\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u039c\u0395\u03a4\u0391\u039e\u0391&#8221;, \u03a0\u03b5\u03b9\u03c1\u03b1\u03b9\u03ac\u03c2<\/li>\n<\/ul>\n<hr \/>\n<p><strong>CARTITUDE 6 A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>Measurable disease, as assessed by central laboratory, at screening as defined by any of the following:<br \/>\na. Serum monoclonal paraprotein (M-protein) level \u22651.0 g\/dL or urine M-protein<br \/>\nlevel \u2265200 mg\/24 hours; or<br \/>\nb. Light-chain MM without measurable disease in serum or urine: serum Ig free<br \/>\nlight chain (FLC) \u226510 mg\/dL and abnormal serum Ig kappa lambda FLC ratio.<br \/>\nNote: Local laboratory assessments may be used to establish measurable disease at<br \/>\nscreening, with local laboratory result \u2265125% of requirements (eg, M-protein \u22651.25 g\/dL if using local laboratories).<br \/>\nECOG performance status of grade 0 or 1<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393 \u039d &#8220;\u0393. \u03a0\u0391\u03a0\u0391\u039d\u0399\u039a\u039f\u039b\u0391\u039f\u03a5&#8221;, \u0398\u03b5\u03c3\u03c3\u03b1\u03bb\u03bf\u03bd\u03af\u03ba\u03b7, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0399. \u03a3\u03b1\u03ba\u03b5\u03bb\u03bb\u03ac\u03c1\u03b7<br \/>\n\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<\/li>\n<\/ul>\n<hr \/>\n<p><strong>EMN 30-MAJESTEC 4 TECLISTAMAB-LENALIDOMIDE VERSUS LENALIDOMIDE MAINTENANCE POST ASCT (<span style=\"color: #ff0000;\">on hold<\/span>)<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u0395\u03b9\u03c3\u03b1\u03b3\u03c9\u03b3\u03b9\u03ba\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 4 \u03ad\u03c9\u03c2 6 \u03ba\u03cd\u03ba\u03bb\u03bf\u03c5\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03bc\u03b5 3 \u03ae 4 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1 \u03bc\u03b5 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 \u03c0\u03c1\u03c9\u03c4\u03b5\u03b1\u03c3\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2 \u03ba\u03b1\u03b9\/\u03ae IMiD\u03bc\u03b5 \u03ae \u03c7\u03c9\u03c1\u03af\u03c2 \u03bc\u03bf\u03bd\u03bf\u03ba\u03bb\u03c9\u03bd\u03b9\u03ba\u03cc antiCD38 \u03b1\u03bd\u03c4\u03af\u03c3\u03c9\u03bc\u03b1 \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bb\u03ae \u03ae \u03b4\u03b9\u03c0\u03bb\u03ae \u03b1\u03c5\u03c4\u03cc\u03bb\u03bf\u03b3\u03b7 \u03bc\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7. Consolidation\u03ad\u03c9\u03c22 \u03ba\u03cd\u03ba\u03bb\u03bf\u03c5\u03c2 \u03b5\u03c0\u03b9\u03c4\u03c1\u03ad\u03c0\u03b5\u03c4\u03b1\u03b9 \u03bc\u03b5 \u03c4\u03b7\u03bd \u03c0\u03c1\u03bf\u03cb\u03c0\u03cc\u03b8\u03b5\u03c3\u03b7 \u03c3\u03c5\u03bd\u03bf\u03bb\u03b9\u03ba\u03ac, \u03bf\u03b9 \u03ba\u03cd\u03ba\u03bb\u03bf\u03b9 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03bc\u03b1\u03b6\u03af \u03bc\u03b5 \u03c4\u03b7\u03bd \u03b5\u03b9\u03c3\u03b1\u03b3\u03c9\u03b3\u03b9\u03ba\u03ae \u03bd\u03b1 \u03bc\u03b7\u03bd \u03be\u03b5\u03c0\u03b5\u03c1\u03bd\u03bf\u03cd\u03bd \u03c4\u03bf\u03c5\u03c2 6. \u039d\u03b1 \u03bc\u03b7\u03bd \u03ad\u03c7\u03b5\u03b9 \u03bb\u03ac\u03b2\u03b5\u03b9 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7\u03c2<br \/>\n\u03a4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd \u03bc\u03b5\u03c1\u03b9\u03ba\u03ae \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7 \u03c3\u03c4\u03b7\u03bd \u03b1\u03c1\u03c7\u03b9\u03ba\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1<br \/>\n\u0388\u03bd\u03b1\u03c1\u03be\u03b7 \u03b1\u03b3\u03c9\u03b3\u03ae\u03c2 \u03b5\u03bd\u03c4\u03cc\u03c2 120 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03b1\u03c0\u03cc \u03b1\u03c5\u03c4\u03cc\u03bb\u03bf\u03b3\u03b7<br \/>\nHb&gt;8, PLTs&gt;75.000, ANC&gt;1000, CrCL&gt;30ml\/min<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u0394\u03b5\u03bd \u03b5\u03c0\u03b9\u03c4\u03c1\u03ad\u03c0\u03b5\u03c4\u03b1\u03b9 \u03bd\u03b1 \u03ad\u03c7\u03b5\u03b9 \u03bb\u03ac\u03b2\u03b5\u03b9 anti-BCMA\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0. \u0393.\u039d. \u0391\u03bb\u03b5\u03be\u03b1\u03bd\u03b4\u03c1\u03bf\u03cd\u03c0\u03bf\u03bb\u03b7\u03c2, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba \u0395.\u03a3\u03c0\u03b1\u03bd\u03bf\u03c5\u03b4\u03ac\u03ba\u03b7\u03c2<br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<\/p>\n<hr \/>\n<p><strong>MAGNETISMM-7 NDMM, MRD positive AND negative after ASCT, ELRANATAMAB (PF-06863135) VS LENALIDOMIDE<\/strong><\/p>\n<p><strong>Elra: c1d1, c1d4, c1d8 (76mg), and QW for 6 cycles, then Q2W<\/strong><br \/>\n<strong>Lena: 10mg QD, increase to 15mg QD after 3cycles<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 \u0394\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7 \u03a0\u039c, 3-8 \u03ba\u03cd\u03ba\u03bb\u03bf\u03b9 \u03b5\u03b9\u03c3\u03b1\u03b3\u03c9\u03b3\u03b9\u03ba\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2, HDM\/ASCT, \u03c4\u03c5\u03c7\u03b1\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u03b5\u03bd\u03c4\u03cc\u03c2 120 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd ASCT\u03ae \u03b5\u03bd\u03c4\u03cc\u03c2 60 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03b1\u03c0\u03cc \u03c4\u03bf consolidation \u03ba\u03b1\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 6 \u03bc\u03b7\u03bd\u03ce\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd ASCT<br \/>\n\u2022 \u03a4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd PR<br \/>\n\u2022 MRD positive (\u226510-5 )[central &#8211; NGS]<br \/>\n\u2022 Must have an archived bone marrow aspirate sample(s) that identifies the dominant malignant (index) clone that is used to track MRD status by central laboratory assessment (Adaptive Biotechnologies clonoSEQ\u00ae assay). This sample should preferably be collected before induction treatment (eg, at diagnosis) or before transplant. A sample collected after transplant may be accepted with sponsor approval.<br \/>\n\u2022 ECOG 0 \u03ae 1<br \/>\n\u2022 eGFR\u226530 mL\/min<br \/>\n\u2022 ANC \u22651000, Platelets \u226575000, Hb \u22658 g\/dL<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 PCL, POEMS, AL<br \/>\n\u2022 QTcF \u2265470 msec<br \/>\n\u2022 \u039d\u03b5\u03c5\u03c1\u03bf\u03c0\u03ac\u03b8\u03b5\u03b9\u03b1Grade \u2265 3, \u03b9\u03c3\u03c4\u03bf\u03c1\u03b9\u03ba\u03cc\u03c3\u03c5\u03bd\u03b4\u03c1\u03cc\u03bc\u03bf\u03c5Guillain-Barre<br \/>\n\u2022 \u0395\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03bc\u03cc\u03c2 \u03bc\u03b5 \u03b5\u03be\u03b1\u03c3\u03b8\u03b5\u03bd\u03b7\u03bc\u03ad\u03bd\u03bf\u03b5\u03bc\u03b2\u03cc\u03bb\u03b9\u03bf\u03b5\u03bd\u03c4\u03cc\u03c2 4 \u03b5\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03c9\u03bd\u03b1\u03c0\u03ccC1D1<br \/>\n\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7\u03c2, \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03b1\u03bd\u03c4\u03b9-BCMA<br \/>\n\u2022 \u0395\u03bd\u03b5\u03c1\u03b3\u03cc\u03c2 \u03bb\u03bf\u03af\u03bc\u03c9\u03be\u03b7, COVID-19, HIV, HBV, HCV<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3. \u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u03b1\u03bd\u03b5\u03c0\u03b9\u03c3\u03c4\u03b7\u03bc\u03b9\u03b1\u03ba\u03cc \u0399\u03c9\u03b1\u03bd\u03bd\u03af\u03bd\u03c9\u03bd, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395. \u03a7\u03b1\u03c4\u03b6\u03b7\u03bc\u03b9\u03c7\u03b1\u03ae\u03bb<br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<\/p>\n<hr \/>\n<p><strong>A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) \u0399\u039c\u039f<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3 &amp; \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 3 \u03ad\u03c9\u03c2 6 \u03ba\u03cd\u03ba\u03bb\u03bf\u03c5\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03b5\u03c0\u03b1\u03b3\u03c9\u03b3\u03ae\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03ad\u03bd\u03b1\u03bd PI \u03ba\u03b1\u03b9 \u03ad\u03bd\u03b1\u03bd IMiD (\u03c0.\u03c7. VTd, RVd) \u03bc\u03b5 \u03ae \u03c7\u03c9\u03c1\u03af\u03c2 \u03bc\u03bf\u03bd\u03bf\u03ba\u03bb\u03c9\u03bd\u03b9\u03ba\u03cc \u03b1\u03bd\u03c4\u03af\u03c3\u03c9\u03bc\u03b1 CD38 \u03ae VCd \u03ba\u03b1\u03b9 \u03b1\u03ba\u03bf\u03bb\u03bf\u03c5\u03b8\u03b5\u03af\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03bc\u03af\u03b1 \u03ae \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 ASCT. \u0395\u03c0\u03b9\u03c4\u03c1\u03ad\u03c0\u03b5\u03c4\u03b1\u03b9 \u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c3\u03c4\u03b1\u03b8\u03b5\u03c1\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7\u03c2 \u03bc\u03b5\u03c4\u03ac \u03c4\u03b7 \u03bc\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7 \u03b1\u03c1\u03c7\u03ad\u03b3\u03bf\u03bd\u03c9\u03bd \u03b1\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03b7\u03c4\u03b9\u03ba\u03ce\u03bd \u03ba\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03bd.<br \/>\n\u2022 \u03a3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03bf\u03bd\u03c4\u03b5\u03c2 \u03b5\u03bd\u03c4\u03cc\u03c2 12 \u03bc\u03b7\u03bd\u03ce\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03ad\u03bd\u03b1\u03c1\u03be\u03b7 \u03c4\u03b7\u03c2 \u03b5\u03c0\u03b1\u03b3\u03c9\u03b3\u03ae\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03ad\u03c4\u03c5\u03c7\u03b1\u03bd \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd PR \u03bc\u03b5\u03c4\u03ac \u03c4\u03b7\u03bd ASCT \u03bc\u03b5 \u03ae \u03c7\u03c9\u03c1\u03af\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c3\u03c4\u03b1\u03b8\u03b5\u03c1\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7\u03c2, \u03c3\u03cd\u03bc\u03c6\u03c9\u03bd\u03b1 \u03bc\u03b5 \u03c4\u03b1 \u03ba\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 IMWG 2016.61 (\u0391\u03bd\u03b1\u03c4\u03c1\u03ad\u03be\u03c4\u03b5 \u03c3\u03c4\u03bf \u03a0\u0391\u03a1\u0391\u03a1\u03a4\u0397\u039c\u0391 6: \u0395\u03bd\u03b9\u03b1\u03af\u03b1 \u03ba\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c4\u03b7\u03c2 \u0394\u03b9\u03b5\u03b8\u03bd\u03bf\u03cd\u03c2 \u039f\u03bc\u03ac\u03b4\u03b1\u03c2 \u0395\u03c1\u03b3\u03b1\u03c3\u03af\u03b1\u03c2 \u03b3\u03b9\u03b1 \u03c4\u03bf \u039c\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1)<br \/>\n\u2022 \u0393\u03b9\u03b1 \u03c4\u03bf\u03c5\u03c2 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03bf\u03bd\u03c4\u03b5\u03c2 \u03c0\u03bf\u03c5 \u03b4\u03b5\u03bd \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c3\u03c4\u03b1\u03b8\u03b5\u03c1\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7\u03c2, \u03bf \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03c9\u03bd \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03b2\u03c1\u03af\u03c3\u03ba\u03b5\u03c4\u03b1\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 120 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03bc\u03b5\u03c4\u03ac \u03c4\u03b7 \u03bc\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7 \u03ba\u03b1\u03c4\u03ac \u03c4\u03bf\u03bd \u03c7\u03c1\u03cc\u03bd\u03bf \u03c4\u03b7\u03c2 \u03c4\u03c5\u03c7\u03b1\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7\u03c2.<br \/>\n\u2022 \u0393\u03b9\u03b1 \u03c4\u03bf\u03c5\u03c2 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03bf\u03bd\u03c4\u03b5\u03c2 \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c3\u03c4\u03b1\u03b8\u03b5\u03c1\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7\u03c2, \u03bf \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03c9\u03bd \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03b2\u03c1\u03af\u03c3\u03ba\u03b5\u03c4\u03b1\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 30\u201360 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03c4\u03b5\u03bb\u03b5\u03c5\u03c4\u03b1\u03af\u03b1 \u03b4\u03cc\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03c3\u03c4\u03b1\u03b8\u03b5\u03c1\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7\u03c2 \u03ba\u03b1\u03c4\u03ac \u03c4\u03bf\u03bd \u03c7\u03c1\u03cc\u03bd\u03bf \u03c4\u03b7\u03c2 \u03c4\u03c5\u03c7\u03b1\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7\u03c2 \u03ba\u03b1\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 180 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03bc\u03b5\u03c4\u03ac \u03c4\u03b7 \u03bc\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7 \u03ba\u03b1\u03c4\u03ac \u03c4\u03bf\u03bd \u03c7\u03c1\u03cc\u03bd\u03bf \u03c4\u03b7\u03c2 \u03c4\u03c5\u03c7\u03b1\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7\u03c2.<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3. \u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393 \u039d &#8220;\u0393. \u03a0\u0391\u03a0\u0391\u039d\u0399\u039a\u039f\u039b\u0391\u039f\u03a5&#8221;, \u0398\u03b5\u03c3\u03c3\u03b1\u03bb\u03bf\u03bd\u03af\u03ba\u03b7, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0399. \u03a3\u03b1\u03ba\u03b5\u03bb\u03bb\u03ac\u03c1\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u0393\u039d \u03a0\u03b1\u03c4\u03c1\u03ce\u03bd, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0391. \u03a3\u03c0\u03c5\u03c1\u03b9\u03b4\u03c9\u03bd\u03af\u03b4\u03b7\u03c2<br \/>\n\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u0393\u03a0\u039d \u039b\u03ac\u03c1\u03b9\u03c3\u03b1\u03c2, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0393. \u0392\u03b1\u03c3\u03b9\u03bb\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2 <span style=\"color: #ff0000;\">(not active yet)<\/span><br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<\/p>\n<hr \/>\n<p><strong>\u00a0\u03a5\u03a0\u039f\u03a4\u03a1\u039f\u03a0\u0399\u0391\u0396\u039f\u039d \u0397\/\u039a\u0391\u0399 \u0391\u039d\u0398\u0395\u039a\u03a4\u0399\u039a\u039f \u03a0\u039f\u039b\u039b\u0391\u03a0\u039b\u039f \u039c\u03a5\u0395\u039b\u03a9\u039c\u0391<\/strong><\/p>\n<p><strong>EFC15951-IRAKLIA: ISAPOMDEXSCvsIV <\/strong><br \/>\n<strong>\u03a4\u03c5\u03c7\u03b1\u03b9\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03b7 \u03c6\u03ac\u03c3\u03b7\u03c2 \u0399\u0399\u0399, \u03c5\u03c0\u03bf\u03b4\u03cc\u03c1\u03b9\u03b1 \u03ad\u03bd\u03b1\u03bd\u03c4\u03b9 \u03b5\u03bd\u03b4\u03bf\u03c6\u03bb\u03ad\u03b2\u03b9\u03b1 \u03b9\u03c3\u03b1\u03c4\u03bf\u03c5\u03be\u03b9\u03bc\u03ac\u03bc\u03c0\u03b7 \u03c3\u03b5 \u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc \u03bc\u03b5 \u03c0\u03bf\u03bc\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7 \u03ba\u03b1\u03b9 \u03b4\u03b5\u03be\u03b1\u03bc\u03b5\u03b8\u03ac\u03b6\u03bf\u03bd\u03b7 \u03c3\u03b5 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 \u03c5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03b9\u03ac\u03b6\u03bf\u03bd\/\u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc \u03c0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03cc \u03bc\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1 (RRMM)<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><br \/>\n\u2022 Mpeak&gt; 0.5 g\/dL, Upeak&gt;200 mg, involved FLC &gt;100 mg\/L abnormal serum FLC ratio<br \/>\n\u2022 \u03a4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 1 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2, \u03ba\u03b1\u03b9 \u03bd\u03b1 \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 2 \u03c3\u03c5\u03bd\u03b5\u03c7\u03cc\u03bc\u03b5\u03bd\u03bf\u03c5\u03c2 \u03ba\u03cd\u03ba\u03bb\u03bf\u03c5\u03c2 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7\u03c2 \u03ba\u03b1\u03b9 \u03ad\u03bd\u03b1 PI (bortezomib, carfilzomib, ixazomib), \u03b5\u03c0\u03b9\u03c4\u03c1\u03ad\u03c0\u03b5\u03c4\u03b1\u03b9 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 ASCT\/consolidation\/maintenance<br \/>\n\u2022 \u039d\u03b1 \u03b5\u03af\u03bd\u03b1\u03b9 Len refractory<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><br \/>\n\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 antiCD38<br \/>\n\u2022 14 \u03bc\u03ad\u03c1\u03b5\u03c2 \u03c7\u03c9\u03c1\u03af\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03b1\u03c0\u03cc c1d1<br \/>\n\u2022 \u039d\u03b1 \u03bc\u03b7\u03bd \u03ad\u03c7\u03bf\u03c5\u03bd \u03b9\u03c3\u03c4\u03bf\u03c1\u03b9\u03ba\u03cc \u03b1\u03bd\u03c4\u03af\u03b4\u03c1\u03b1\u03c3\u03b7\u03c2 \u03c3\u03c4\u03b7 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u0393\u039d \u03a0\u03b1\u03c4\u03c1\u03ce\u03bd, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0391. \u03a3\u03c0\u03c5\u03c1\u03b9\u03b4\u03c9\u03bd\u03af\u03b4\u03b7\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393 \u039d &#8220;\u0393. \u03a0\u0391\u03a0\u0391\u039d\u0399\u039a\u039f\u039b\u0391\u039f\u03a5&#8221;, \u0398\u03b5\u03c3\u03c3\u03b1\u03bb\u03bf\u03bd\u03af\u03ba\u03b7, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u039c. \u0399\u03c3\u03ba\u03ac\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u03b1\u03bd\u03b5\u03c0\u03b9\u03c3\u03c4\u03b7\u03bc\u03b9\u03b1\u03ba\u03cc \u0399\u03c9\u03b1\u03bd\u03bd\u03af\u03bd\u03c9\u03bd, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u0395. \u039a\u03b1\u03c8\u03ac\u03bb\u03b7<br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<\/p>\n<hr \/>\n<p><strong>\u0395\u0391\u0395115 ISA-POM-DEX 2\u03b7 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae \u201cA PHASE 2 STUDY OF ISATUXIMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN MM PATIENTS WHO RECEIVED ONE PRIOR LINE OF THERAPY CONTAINING LENALIDOMIDE AND A PROTEASOME INHIBITOR\u201d<br \/>\n<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 \u0391\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03c0\u03bf\u03c5 \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u039c\u039f\u039d\u039f \u03bc\u03af\u03b1 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03ad\u03bd\u03b1\u03bd\u03c4\u03b9 \u03c4\u03bf\u03c5 \u03bc\u03c5\u03b5\u03bb\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2, \u03b7 \u03bf\u03c0\u03bf\u03af\u03b1 \u03c3\u03c5\u03bc\u03c0\u03b5\u03c1\u03b9\u03b5\u03bb\u03ac\u03bc\u03b2\u03b1\u03bd\u03b5 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7 (\u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 2<br \/>\n\u2022 \u03ba\u03cd\u03ba\u03bb\u03bf\u03c5\u03c2, \u03b5\u03af\u03c4\u03b5 \u03c9\u03c2 \u03bc\u03bf\u03bd\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03b5\u03af\u03c4\u03b5 \u03c3\u03b5 \u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc) \u03ba\u03b1\u03b9 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 \u03c0\u03c1\u03c9\u03c4\u03b5\u03b1\u03c3\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2 (\u03c0.\u03c7. \u03b2\u03bf\u03c1\u03c4\u03b5\u03b6\u03bf\u03bc\u03af\u03bc\u03c0\u03b7, \u03ba\u03b1\u03c1\u03c6\u03b9\u03bb\u03b6\u03bf\u03bc\u03af\u03bc\u03c0\u03b7, \u03b9\u03be\u03b1\u03b6\u03bf\u03bc\u03af\u03bc\u03c0\u03b7).<br \/>\n\u2022 \u039c-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u2265 0,5g\/dL \u03ba\u03b1\u03b9\/\u03aeU-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u2265200 mg\/24 \u03ce\u03c1\u03b5\u03c2 \u03ae \u0395\u03bb\u03b5\u03cd\u03b8\u03b5\u03c1\u03b7 \u03b5\u03bb\u03b1\u03c6\u03c1\u03b9\u03ac \u03b1\u03bb\u03c5\u03c3\u03af\u03b4\u03b1 \u03b1\u03bd\u03bf\u03c3\u03bf\u03c3\u03c6\u03b1\u03b9\u03c1\u03b9\u03bd\u03ce\u03bd \u03bf\u03c1\u03bf\u03cd \u226510 mg\/dL \u03ba\u03b1\u03b9 \u03c0\u03b1\u03b8\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc\u03c2 \u03bb\u03cc\u03b3\u03bf\u03c2<br \/>\n\u2022 ANC \u22651,0 x109\/L, Hb \u22657,5 g\/dL, PLTs \u226575 x 109<br \/>\n\u2022 4.ALT\u22642,5 xULN, AST \u22642,5 xULN, t.bil\u22641,5 xULN<br \/>\n\u2022 eGFR \u226530 mL\/\u03bb\u03b5\u03c0\u03c4\u03cc (CG)<br \/>\n\u2022 ECOGPS \u22642<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03b1\u03bd\u03c4\u03b9-CD38<br \/>\n\u2022 ASCT \u03b5\u03bd\u03c4\u03cc\u03c2 12 \u03b5\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03c9\u03bd \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03c4\u03bf\u03bd C1d1<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u0393\u039d \u03a0\u03b1\u03c4\u03c1\u03ce\u03bd<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u03b1\u03bd\u03b5\u03c0\u03b9\u03c3\u03c4\u03b7\u03bc\u03b9\u03b1\u03ba\u03cc \u0399\u03c9\u03b1\u03bd\u03bd\u03af\u03bd\u03c9\u03bd<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u0393\u03a0\u039d \u039b\u03ac\u03c1\u03b9\u03c3\u03b1\u03c2, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u039d. \u0393\u03b9\u03b1\u03bd\u03bd\u03b1\u03ba\u03bf\u03cd\u03bb\u03b9\u03b1\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0. \u0393.\u039d. \u0391\u03bb\u03b5\u03be\u03b1\u03bd\u03b4\u03c1\u03bf\u03cd\u03c0\u03bf\u03bb\u03b7\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u039c\u0395\u03a4\u0391\u039e\u0391&#8221;, \u03a0\u03b5\u03b9\u03c1\u03b1\u03b9\u03ac\u03c2<br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395. \u03a4\u03ad\u03c1\u03c0\u03bf\u03c2<\/p>\n<hr \/>\n<p><strong>\u0395\u0391\u0395127: DARA-BELA-POM-DEX: \u039c\u0399\u0391 \u039c\u0395\u039b\u0395\u03a4\u0397 \u0391\u039e\u0399\u039f\u039b\u039f\u0393\u0397\u03a3\u0397\u03a3 \u0394\u039f\u03a3\u039f\u039b\u039f\u0393\u0399\u039a\u039f\u03a5 \u03a3\u03a7\u0397\u039c\u0391\u03a4\u039f\u03a3, \u03a6\u0391\u03a3\u0397\u03a3 1\/2, \u0393\u0399\u0391 \u03a4\u0397 \u0394\u0399\u0395\u03a1\u0395\u03a5\u039d\u0397\u03a3\u0397 \u03a4\u0397\u03a3 \u0391\u03a3\u03a6\u0391\u039b\u0395\u0399\u0391\u03a3 \u039a\u0391\u0399 \u03a4\u0397\u03a3 \u039a\u039b\u0399\u039d\u0399\u039a\u0397\u03a3 \u0394\u03a1\u0391\u03a3\u03a4\u0397\u03a1\u0399\u039f\u03a4\u0397\u03a4\u0391\u03a3 \u03a4\u0397\u03a3 \u039c\u03a0\u0395\u039b\u0391\u039d\u03a4\u0391\u039c\u0391\u039c\u03a0\u0397\u03a3 \u039c\u0391\u03a6\u039f\u0394\u039f\u03a4\u0399\u039d\u0397\u03a3 \u03a7\u039f\u03a1\u0397\u0393\u039f\u03a5\u039c\u0395\u039d\u0397\u03a3 \u03a3\u0395 \u03a3\u03a5\u039d\u0394\u03a5\u0391\u03a3\u039c\u039f \u039c\u0395 \u0394\u0391\u03a1\u0391\u03a4\u039f\u03a5\u039c\u039f\u03a5\u039c\u0391\u039c\u03a0\u0397, \u03a0\u039f\u039c\u0391\u039b\u0399\u0394\u039f\u039c\u0399\u0394\u0397 \u039a\u0391\u0399 \u0394\u0395\u039e\u0391\u039c\u0395\u0398\u0391\u0396\u039f\u039d\u0397 \u03a3\u0395 \u0391\u03a3\u0398\u0395\u039d\u0395\u0399\u03a3 \u039c\u0395 \u03a5\u03a0\u039f\u03a4\u03a1\u039f\u03a0\u0399\u0391\u0396\u039f\u039d\/\u0391\u039d\u0398\u0395\u039a\u03a4\u0399\u039a\u039f \u03a0\u039f\u039b\u039b\u0391\u03a0\u039b\u039f \u039c\u03a5\u0395\u039b\u03a9\u039c\u0391 \u03a0\u039f\u03a5 \u0395\u03a7\u039f\u03a5\u039d \u039b\u0391\u0392\u0395\u0399 \u03a0\u03a1\u039f\u0397\u0393\u039f\u03a5\u039c\u0395\u039d\u03a9\u03a3 \u039c\u0399\u0391 \u0393\u03a1\u0391\u039c\u039c\u0397 \u0398\u0395\u03a1\u0391\u03a0\u0395\u0399\u0391\u03a3 \u039a\u0391\u0399 \u0395\u0399\u039d\u0391\u0399 \u0391\u039d\u0398\u0395\u039a\u03a4\u0399\u039a\u039f\u0399 \u03a3\u03a4\u0397 \u039b\u0395\u039d\u0391\u039b\u0399\u0394\u039f\u039c\u0399\u0394\u0397<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 \u03a0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03b4\u03b9\u03b1\u03b8\u03ad\u03c4\u03bf\u03c5\u03bd \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd \u039c\u0399\u0391 \u03c3\u03c5\u03bd\u03b9\u03c3\u03c4\u03ce\u03c3\u03b1 \u03bc\u03b5\u03c4\u03c1\u03ae\u03c3\u03b9\u03bc\u03b7\u03c2 \u03bd\u03cc\u03c3\u03bf\u03c5, \u03b7 \u03bf\u03c0\u03bf\u03af\u03b1 \u03bf\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03c9\u03c2 \u03ad\u03bd\u03b1 \u03b1\u03c0\u03cc \u03c4\u03b1 \u03b1\u03ba\u03cc\u03bb\u03bf\u03c5\u03b8\u03b1:<br \/>\na. \u0391\u03c0\u03ad\u03ba\u03ba\u03c1\u03b9\u03c3\u03b7 \u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2 \u039c \u03c3\u03c4\u03b1 \u03bf\u03cd\u03c1\u03b1 \u2265200 mg\/24 \u03ce\u03c1\u03b5\u03c2 (\u22650,2g\/24 \u03ce\u03c1\u03b5\u03c2), \u03ae<br \/>\nb. \u03a3\u03c5\u03b3\u03ba\u03ad\u03bd\u03c4\u03c1\u03c9\u03c3\u03b7 \u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2 \u039c \u03c3\u03c4\u03bf\u03bd \u03bf\u03c1\u03cc \u22650,5 g\/dL (\u22655,0 g\/L), \u03ae<br \/>\nc. \u0394\u03bf\u03ba\u03b9\u03bc\u03b1\u03c3\u03af\u03b1 \u03b5\u03bb\u03b5\u03cd\u03b8\u03b5\u03c1\u03b7\u03c2 \u03b5\u03bb\u03b1\u03c6\u03c1\u03b9\u03ac\u03c2 \u03b1\u03bb\u03cd\u03c3\u03bf\u03c5 (FLC) \u03bf\u03c1\u03bf\u03cd: \u03b5\u03c0\u03af\u03c0\u03b5\u03b4\u03bf \u03b5\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03b7\u03c2<br \/>\nFLC \u226510 mg\/dL (\u2265100 mg\/L) \u03ba\u03b1\u03b9 \u03bc\u03b7 \u03c6\u03c5\u03c3\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc\u03c2 \u03bb\u03cc\u03b3\u03bf\u03c2 FLC (&lt;0,26 \u03ae<br \/>\n&gt;1,65).<br \/>\n\u2022 \u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c1\u03c5\u03b8\u03bc\u03cc\u03c2 \u03c3\u03c0\u03b5\u03b9\u03c1\u03b1\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae\u03c2 \u03b4\u03b9\u03ae\u03b8\u03b7\u03c3\u03b7\u03c2 (eGFR) \u2265 30 L\/\u03bb\u03b5\u03c0\u03c4\u03cc\/1,73m2 . \u03a5\u03c0\u03bf\u03bb\u03bf\u03b3\u03af\u03c3\u03c4\u03b7\u03ba\u03b5 \u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03ce\u03bd\u03c4\u03b1\u03c2 \u03c4\u03bf\u03bd \u03c4\u03cd\u03c0\u03bf \u03a4\u03c1\u03bf\u03c0\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03b7\u03c2 \u0394\u03b9\u03b1\u03c4\u03c1\u03bf\u03c6\u03ae\u03c2 \u03c3\u03c4\u03b7 \u039d\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u039d\u03cc\u03c3\u03bf (MDRD).<br \/>\n\u2022 \u039f \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03c9\u03bd \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03ad\u03c7\u03b5\u03b9 \u03bb\u03ac\u03b2\u03b5\u03b9 \u03bc\u03cc\u03bd\u03bf 1 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 (\u03c3\u03c5\u03bc\u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03b1\u03bd\u03bf\u03bc\u03ad\u03bd\u03b7\u03c2 \u03c4\u03b7\u03c2 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7\u03c2) \u03ba\u03b1\u03b9 \u03bd\u03b1 \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc\u03c2 \u03c3\u03c4\u03b7 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7 \u03c3\u03b5 \u03bf\u03c0\u03bf\u03b9\u03b1\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03b4\u03cc\u03c3\u03b7 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7\u03c2 (\u03b4\u03b7\u03bb, \u03bd\u03b1 \u03bc\u03b7\u03bd \u03b1\u03bd\u03c4\u03b1\u03c0\u03bf\u03ba\u03c1\u03af\u03bd\u03b5\u03c4\u03b1\u03b9 \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7 \u03b4\u03b9\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03c4\u03b7\u03c2 \u03bb\u03ae\u03c8\u03b7\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03bc\u03b5 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7, \u03ae \u03bd\u03b1 \u03ad\u03c7\u03b5\u03b9 \u03b5\u03bc\u03c6\u03b1\u03bd\u03af\u03c3\u03b5\u03b9 \u03b5\u03be\u03ad\u03bb\u03b9\u03be\u03b7 \u03c4\u03b7\u03c2 \u03bd\u03cc\u03c3\u03bf\u03c5 \u03b5\u03bd\u03c4\u03cc\u03c2 60 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03c4\u03b5\u03bb\u03b5\u03c5\u03c4\u03b1\u03af\u03b1 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7)<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395. \u03a4\u03ad\u03c1\u03c0\u03bf\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<\/p>\n<hr \/>\n<p><strong>EXCALIBER IberDd vs DVd (\u03c6\u03ac\u03c3\u03b7 3)<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 \u03a0\u03bf\u03c3\u03cc\u03c4\u03b7\u03c4\u03b5\u03c2 \u039c-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2 \u2265 1 g\/dL \u03bc\u03ad\u03c3\u03c9 \u03b7\u03bb\u03b5\u03ba\u03c4\u03c1\u03bf\u03c6\u03cc\u03c1\u03b7\u03c3\u03b7\u03c2 \u03c0\u03c1\u03c9\u03c4\u03b5\u03ca\u03bd\u03ce\u03bd \u03bf\u03c1\u03bf\u03cd (sPEP) \u03ae\u03c3\u03c5\u03bb\u03bb\u03bf\u03b3\u03ae\u03c2 \u03bf\u03cd\u03c1\u03c9\u03bd 24\u03ce\u03c1\u03bf\u03c5 \u2265 200 mg \u03bc\u03ad\u03c3\u03c9 \u03b7\u03bb\u03b5\u03ba\u03c4\u03c1\u03bf\u03c6\u03cc\u03c1\u03b7\u03c3\u03b7\u03c2 \u03c0\u03c1\u03c9\u03c4\u03b5\u03ca\u03bd\u03ce\u03bd \u03bf\u03cd\u03c1\u03c9\u03bd (uPEP)\u03ae\u03a0\u039c \u03b5\u03bb\u03b1\u03c6\u03c1\u03b9\u03ac\u03c2 \u03b1\u03bb\u03c5\u03c3\u03af\u03b4\u03b1\u03c2 \u03c7\u03c9\u03c1\u03af\u03c2 \u03bc\u03b5\u03c4\u03c1\u03ae\u03c3\u03b9\u03bc\u03b7 \u03bd\u03cc\u03c3\u03bf \u03c3\u03c4\u03bf\u03bd \u03bf\u03c1\u03cc \u03ae \u03c3\u03c4\u03b1 \u03bf\u03cd\u03c1\u03b1: \u03b5\u03c0\u03af\u03c0\u03b5\u03b4\u03b1\u03b5\u03bb\u03b5\u03cd\u03b8\u03b5\u03c1\u03b7\u03c2 \u03b5\u03bb\u03b1\u03c6\u03c1\u03ac\u03c2 \u03b1\u03bb\u03c5\u03c3\u03af\u03b4\u03b1\u03c2 (FLC) \u03bf\u03c1\u03bf\u03cd &gt; 100 mg\/L (10 mg\/dL) \u03bc\u03b5 \u03b5\u03bb\u03b1\u03c6\u03c1\u03b9\u03ac\u03b1\u03bb\u03c5\u03c3\u03af\u03b4\u03b1 \u03ba\u03b1\u03b9 \u03bc\u03b9\u03b1 \u03bc\u03b7 \u03c6\u03c5\u03c3\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03b1\u03bd\u03b1\u03bb\u03bf\u03b3\u03af\u03b1 FLC \u03ba\u03ac\u03c0\u03b1\/\u03bb\u03ac\u03bc\u03b4\u03b1<br \/>\n\u2022 \u0391\u03c3\u03b8\u03b5\u03bd\u03ae\u03c2 \u03c0\u03bf\u03c5 \u03ad\u03c7\u03b5\u03b9 \u03bb\u03ac\u03b2\u03b5\u03b9 1 \u03ad\u03c9\u03c2 2 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03ba\u03b1\u03c4\u03ac \u03c4\u03bf\u03c5 \u03bc\u03c5\u03b5\u03bb\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2.<br \/>\n\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b1\u03b3\u03c9\u03b3\u03ae \u03bc\u03b5 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03ba\u03b1\u03c4\u03ac \u03c4\u03bf\u03c5 CD38:\u03a3\u03c4\u03bf \u03a3\u03c4\u03ac\u03b4\u03b9\u03bf 1, \u03bf\u03b9 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03c0\u03bf\u03c5 \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03ba\u03b1\u03c4\u03ac \u03c4\u03bf\u03c5 CD38 \u03b4\u03b5\u03bd \u03b5\u03af\u03bd\u03b1\u03b9 \u03ba\u03b1\u03c4\u03ac\u03bb\u03bb\u03b7\u03bb\u03bf\u03b9. \u03a3\u03c4\u03bf \u03c3\u03c4\u03ac\u03b4\u03b9\u03bf 2, \u03b7 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b1\u03b3\u03c9\u03b3\u03ae \u03bc\u03b5 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03ba\u03b1\u03c4\u03ac \u03c4\u03bf\u03c5 CD38 \u03b5\u03c0\u03b9\u03c4\u03c1\u03ad\u03c0\u03b5\u03c4\u03b1\u03b9 \u03bc\u03cc\u03bd\u03bf \u03b5\u03ac\u03bd \u03c0\u03bb\u03b7\u03c1\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03ba\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1<br \/>\n\u2022 \u0397 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b1\u03b3\u03c9\u03b3\u03ae \u03bc\u03b5 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03b2\u03bf\u03c1\u03c4\u03b5\u03b6\u03bf\u03bc\u03af\u03bc\u03c0\u03b7 \u03b5\u03c0\u03b9\u03c4\u03c1\u03ad\u03c0\u03b5\u03c4\u03b1\u03b9 \u03bc\u03cc\u03bd\u03bf \u03b5\u03ac\u03bd \u03c0\u03bb\u03b7\u03c1\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03cc\u03bb\u03b1 \u03c4\u03b1 \u03c0\u03b1\u03c1\u03b1\u03ba\u03ac\u03c4\u03c9: \u03b1. \u0397 \u03b2\u03ad\u03bb\u03c4\u03b9\u03c3\u03c4\u03b7 \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7 \u03c0\u03bf\u03c5 \u03b5\u03c0\u03b9\u03c4\u03b5\u03cd\u03c7\u03b8\u03b7\u03ba\u03b5 \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7 \u03b4\u03b9\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03c4\u03b7\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03bc\u03b5 \u03b2\u03bf\u03c1\u03c4\u03b5\u03b6\u03bf\u03bc\u03af\u03bc\u03c0\u03b7 \u03ae\u03c4\u03b1\u03bd \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd \u03bc\u03b9\u03b1 \u03b5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03b7 \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7 (MR).\u03b2. \u039f \u03b1\u03c3\u03b8\u03b5\u03bd\u03ae\u03c2 \u03b4\u03b5\u03bd \u03c0\u03b1\u03c1\u03bf\u03c5\u03c3\u03af\u03b1\u03c3\u03b5 \u03b5\u03be\u03ad\u03bb\u03b9\u03be\u03b7 \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7 \u03bb\u03ae\u03c8\u03b7 \u03c4\u03b7\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03bc\u03b5 \u03b2\u03bf\u03c1\u03c4\u03b5\u03b6\u03bf\u03bc\u03af\u03bc\u03c0\u03b7 \u03ae \u03b5\u03bd\u03c4\u03cc\u03c2 60 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03c4\u03b5\u03bb\u03b5\u03c5\u03c4\u03b1\u03af\u03b1 \u03b4\u03cc\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2.<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 ANC &lt; 1.000\/\u03bcL.<br \/>\n\u2022 PLTs&lt; 50.000\/\u03bcL<br \/>\n\u2022 \u0391\u03b9\u03bc\u03bf\u03c3\u03c6\u03b1\u03b9\u03c1\u03af\u03bd\u03b7 &lt; 8 g\/dL<br \/>\n\u2022 eGFR&lt; 30 mL\/min\/1,73m2 MDRD<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u039c. \u0393\u03b1\u03b2\u03c1\u03b9\u03b1\u03c4\u03bf\u03c0\u03bf\u03cd\u03bb\u03bf\u03c5<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u0393\u039d \u03a0\u03b1\u03c4\u03c1\u03ce\u03bd, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0391. \u03a3\u03c0\u03c5\u03c1\u03b9\u03b4\u03c9\u03bd\u03af\u03b4\u03b7\u03c2<\/p>\n<hr \/>\n<p><strong>MAGNETISMM-5 \u03bd\u03bf\u03c3\u03b7\u03bb\u03b5\u03af\u03b1 day1-5 \u03a4\u03c5\u03c7\u03b1\u03b9\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03b7 \u03bc\u03b5\u03bb\u03ad\u03c4\u03b7 \u03c6\u03ac\u03c3\u03b7\u03c2 3, RRMM after 1 prior lena+PI (on hold)<\/strong><br \/>\n<strong>ELRANATAMAB \u03bc\u03bf\u03bd\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 vs ELRANATAMAB + DARA vs DARAPOMDEX<\/strong><br \/>\n<strong>(Elra: c1d1, c1d4, c1d8 (44\/76mg), and QW for 6 cycles, then Q2W)<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u039c\u03b5\u03c4\u03c1\u03ae\u03c3\u03b9\u03bc\u03b7 \u03bd\u03cc\u03c3\u03bf\u03c2<br \/>\n\u2022 Serum M-protein \u22650.5 g\/dL;<br \/>\n\u2022 Urinary M-protein excretion \u2265200 mg\/24 hours;<br \/>\n\u2022 Serum immunoglobulin FLC \u226510 mg\/dL (\u2265100 mg\/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (1.65).<br \/>\n\u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2<br \/>\na. Part 1: \u03a4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 3 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2, \u03c3\u03c5\u03bc\u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03b1\u03bd\u03bf\u03bc\u03ad\u03bd\u03c9\u03bd\u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7\u03c2\u03ba\u03b1\u03b9PI.<br \/>\nb. Part 2: 1-4 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2, \u03c3\u03c5\u03bc\u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03b1\u03bd\u03bf\u03bc\u03ad\u03bd\u03c9\u03bd \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7\u03c2 \u03ba\u03b1\u03b9 PI. \u03a3\u03b5 \u03b1\u03c5\u03c4\u03cc \u03c4\u03bf \u03c3\u03ba\u03ad\u03bb\u03bf\u03c2 \u03ba\u03ac\u03bd\u03bf\u03c5\u03bc\u03b5 recruitment<br \/>\n\u2022 ECOG 0-2<br \/>\n\u2022 eGFR \u226530 mL\/min<br \/>\n\u2022 ANC \u22651000, Platelets \u226575000, Hb \u22658 g\/dL<br \/>\n\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b1\u0391\u0395sGrade \u22641.<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 PCL, POEMS, AL, sMM, WM, CNS\u03b4\u03b9\u03ae\u03b8\u03b7\u03c3\u03b7<br \/>\n\u2022 QTcF \u2265470 msec<br \/>\n\u2022 ASCT\u03b5\u03bd\u03c4\u03cc\u03c2 12 \u03b5\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03c9\u03bd.<br \/>\n\u2022 \u039d\u03b5\u03c5\u03c1\u03bf\u03c0\u03ac\u03b8\u03b5\u03b9\u03b1Grade \u2265 2, \u03b9\u03c3\u03c4\u03bf\u03c1\u03b9\u03ba\u03cc\u03c3\u03c5\u03bd\u03b4\u03c1\u03cc\u03bc\u03bf\u03c5Guillain-Barre<br \/>\n\u2022 \u0395\u03bd\u03b5\u03c1\u03b3\u03cc\u03c2\u03bb\u03bf\u03af\u03bc\u03c9\u03be\u03b7, COVID-19, HIV, HBV, HCV<br \/>\n\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03b1\u03bd\u03c4\u03b9-BCMA, anti-CD3<br \/>\n\u2022 Anti-CD38 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03b5\u03bd\u03c4\u03cc\u03c2 6 \u03bc\u03b7\u03bd\u03ce\u03bd \u03b1\u03c0\u03cc C1D1<br \/>\n\u2022 Part 2 only:\u0391\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1\u03c3\u03b5\u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7anti-CD38 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1, \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03bc\u03b5\u03c0\u03bf\u03bc\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7, \u03b9\u03c3\u03c7\u03c5\u03c1\u03bf\u03af\u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2CYP1A2,&gt;10 mgQDprednisone (\u03ae \u03b9\u03c3\u03bf\u03b4\u03cd\u03bd\u03b1\u03bc\u03bf) \u03b5\u03bd\u03c4\u03cc\u03c2 14 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd\u03ae5 \u03c7\u03c1\u03cc\u03bd\u03c9\u03bd \u03b7\u03bc\u03af\u03c3\u03b5\u03b9\u03b1\u03c2 \u03b6\u03c9\u03ae\u03c2 \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc C1D1\u03c0\u03bf\u03bc\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7\u03c2<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u03b1\u03bd\u03b5\u03c0\u03b9\u03c3\u03c4\u03b7\u03bc\u03b9\u03b1\u03ba\u03cc \u0399\u03c9\u03b1\u03bd\u03bd\u03af\u03bd\u03c9\u03bd, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395. \u03a7\u03b1\u03c4\u03b6\u03b7\u03bc\u03b9\u03c7\u03b1\u03ae\u03bb<\/p>\n<hr \/>\n<p><strong>DREAMM 5 \/ Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed\/\u200bRefractory Multiple Myeloma<\/strong><\/p>\n<p><strong>NCT04126200<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 \u03a4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 3 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03c0\u03bf\u03c5 \u03bd\u03b1 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd IMID, PI \u03ba\u03b1\u03b9 anti-CD38 \u03bc\u03bf\u03bd\u03bf\u03ba\u03bb\u03c9\u03bd\u03b9\u03ba\u03cc \u03b1\u03bd\u03c4\u03af\u03c3\u03c9\u03bc\u03b1.<br \/>\n\u2022 \u039c\u03b5\u03c4\u03c1\u03ae\u03c3\u03b9\u03bc\u03b7 \u03bd\u03cc\u03c3\u03bf\u03c2 (\u03b3\u03b9\u03b1Mpeak&gt;0,5g.dl, EGFR&gt;30ml\/min<br \/>\n\u2022 ANC&gt;1000, Hb&gt;8g\/dl, PLTs&gt;50.000<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<\/p>\n<hr \/>\n<p><strong>EMN29 A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 1 \u03ad\u03c9\u03c2 4 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2\u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2<br \/>\n\u2022 \u03a4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 1 PI, 1 IMiD, 1 anti-CD38<br \/>\n\u2022 eGFR\u226515 mL\/min<br \/>\n\u2022 ANC \u22651500, Platelets \u2265100000 \u03ae 75000 (\u03b1\u03bd \u226550% \u03b4\u03b9\u03ae\u03b8\u03b7\u03c3\u03b7\u03bc\u03c5\u03b5\u03bb\u03bf\u03cd), Hb \u22658.5 g\/dL<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 PCL, POEMS, AL, sMM, \u03b4\u03b9\u03ae\u03b8\u03b7\u03c3\u03b7 \u039a\u039d\u03a3<br \/>\n\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b1\u03b3\u03c9\u03b3\u03ae \u03bc\u03b5 XPO1 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2, \u03c0\u03bf\u03bc\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7, \u03b5\u03bb\u03bf\u03c4\u03bf\u03c5\u03b6\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7<br \/>\n\u2022 ASCT&lt; 60 \u03b7\u03bc\u03ad\u03c1\u03b5\u03c2\u03b1\u03c0\u03ccC1D1<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u0393\u039d \u03a0\u03b1\u03c4\u03c1\u03ce\u03bd, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0391. \u03a3\u03c0\u03c5\u03c1\u03b9\u03b4\u03c9\u03bd\u03af\u03b4\u03b7\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395. \u03a4\u03ad\u03c1\u03c0\u03bf\u03c2<\/p>\n<hr \/>\n<p><strong>XPORT-MM-028 &#8211; A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3 &amp; \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 \u039c\u03b5\u03c4\u03c1\u03ae\u03c3\u03b9\u03bc\u03b7 \u03bd\u03cc\u03c3\u03bf\u03c2 \u03bc\u03b5 Mpeak&gt;0,5g\/dl \u03ae Upeak&gt;200mg \u03ae FLC&gt;100<br \/>\n\u2022 \u0393\u03b9\u03b1 \u03c4\u03b1 ARMSSd-40 BIW, Sd-100 QW \u03ba\u03b1\u03b9 Sd-80 BIW\u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 4 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03ba\u03b1\u03b9 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1 \u03c3\u03b5 2 PIs, 2 IMiDS \u03ba\u03b1\u03b9 1 anti-CD38 \u03bc\u03bf\u03bd\u03bf\u03ba\u03bb\u03c9\u03bd\u03b9\u03ba\u03cc \u03b1\u03bd\u03c4\u03af\u03c3\u03c9\u03bc\u03b1<br \/>\n\u2022 Creatinineclearance&gt;20 ml\/min<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u039c. \u0393\u03b1\u03b2\u03c1\u03b9\u03b1\u03c4\u03bf\u03c0\u03bf\u03cd\u03bb\u03bf\u03c5<\/p>\n<hr \/>\n<p><strong>SUCCESOR -1 : \u03a6\u0391\u03a3\u0397\u03a3 3, \u0394\u03a5\u039f \u03a3\u03a4\u0391\u0394\u0399\u03a9\u039d, \u03a4\u03a5\u03a7\u0391\u0399\u039f\u03a0\u039f\u0399\u0397\u039c\u0395\u039d\u0397, \u03a0\u039f\u039b\u03a5\u039a\u0395\u039d\u03a4\u03a1\u0399\u039a\u0397, \u0391\u039d\u039f\u0399\u039a\u03a4\u0397 \u039c\u0395\u039b\u0395\u03a4\u0397 \u03a3\u03a5\u0393\u039a\u03a1\u0399\u03a3\u0397\u03a3 \u03a4\u039f\u03a5 \u03a3\u03a5\u039d\u0394\u03a5\u0391\u03a3\u039c\u039f\u03a5 CC-92480, \u0392\u039f\u03a1\u03a4\u0395\u0396\u039f\u039c\u0399\u039c\u03a0\u0397\u03a3 \u039a\u0391\u0399 \u0394\u0395\u039e\u0391\u039c\u0395\u0398\u0391\u0396\u039f\u039d\u0397\u03a3 (480Vd) \u0395\u039d\u0391\u039d\u03a4\u0399 \u03a4\u039f\u03a5 \u03a3\u03a5\u039d\u0394\u03a5\u0391\u03a3\u039c\u039f\u03a5 \u03a0\u039f\u039c\u0391\u039b\u0399\u0394\u039f\u039c\u0399\u0394\u0397\u03a3, \u0392\u039f\u03a1\u03a4\u0395\u0396\u039f\u039c\u0399\u039c\u03a0\u0397\u03a3 \u039a\u0391\u0399 \u0394\u0395\u039e\u0391\u039c\u0395\u0398\u0391\u0396\u039f\u039d\u0397\u03a3 (PVd) \u03a3\u0395 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u039d\u03a4\u0395\u03a3 \u039c\u0395 \u03a5\u03a0\u039f\u03a4\u03a1\u039f\u03a0\u0399\u0391\u0396\u039f\u039d \u0397 \u0391\u039d\u0398\u0395\u039a\u03a4\u0399\u039a\u039f \u03a0\u039f\u039b\u039b\u0391\u03a0\u039b\u039f \u039c\u03a5\u0395\u039b\u03a9\u039c\u0391 (RRMM)\u00a0<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>1) \u039f \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03c9\u03bd \u03ad\u03c7\u03b5\u03b9 \u03c4\u03b5\u03ba\u03bc\u03b7\u03c1\u03b9\u03c9\u03bc\u03ad\u03bd\u03b7 \u03b4\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7 \u03a0\u039c \u03ba\u03b1\u03b9 \u03bc\u03b5\u03c4\u03c1\u03ae\u03c3\u03b9\u03bc\u03b7 \u03bd\u03cc\u03c3\u03bf, \u03c0\u03bf\u03c5 \u03bf\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03c9\u03c2 \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b1 \u03b1\u03ba\u03cc\u03bb\u03bf\u03c5\u03b8\u03b1:<br \/>\na. M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u2265 0,5 g\/dL \u03bc\u03ad\u03c3\u03c9 \u03b7\u03bb\u03b5\u03ba\u03c4\u03c1\u03bf\u03c6\u03cc\u03c1\u03b7\u03c3\u03b7\u03c2 \u03c0\u03c1\u03c9\u03c4\u03b5\u03ca\u03bd\u03ce\u03bd \u03bf\u03c1\u03bf\u03cd (sPEP), \u03ae<br \/>\nb. M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u2265 200 mg\/\u03c3\u03c5\u03bb\u03bb\u03bf\u03b3\u03ae \u03bf\u03cd\u03c1\u03c9\u03bd 24\u03c9\u03c1\u03bf\u03c5 \u03bc\u03ad\u03c3\u03c9 \u03b7\u03bb\u03b5\u03ba\u03c4\u03c1\u03bf\u03c6\u03cc\u03c1\u03b7\u03c3\u03b7\u03c2 \u03c0\u03c1\u03c9\u03c4\u03b5\u03ca\u03bd\u03ce\u03bd \u03bf\u03cd\u03c1\u03c9\u03bd (uPEP), \u03ae<br \/>\nc. \u0393\u03b9\u03b1 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03bf\u03bd\u03c4\u03b5\u03c2 \u03c7\u03c9\u03c1\u03af\u03c2 \u03bc\u03b5\u03c4\u03c1\u03ae\u03c3\u03b9\u03bc\u03b7 \u03bd\u03cc\u03c3\u03bf \u03c3\u03b5 sPEP \u03ae uPEP: \u03b5\u03c0\u03af\u03c0\u03b5\u03b4\u03b1 \u03b5\u03bb\u03b5\u03cd\u03b8\u03b5\u03c1\u03c9\u03bd \u03b5\u03bb\u03b1\u03c6\u03c1\u03ce\u03bd \u03b1\u03bb\u03c5\u03c3\u03af\u03b4\u03c9\u03bd\u03c3\u03c4\u03bf\u03bd \u03bf\u03c1\u03cc (sFLC); 100 mg\/L (10 mg\/dL) \u03b5\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03b7\u03c2 \u03b5\u03bb\u03b1\u03c6\u03c1\u03ac\u03c2 \u03b1\u03bb\u03c5\u03c3\u03af\u03b4\u03b1\u03c2 \u03ba\u03b1\u03b9 \u03bc\u03b7 \u03c6\u03c5\u03c3\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03b1\u03bd\u03b1\u03bb\u03bf\u03b3\u03af\u03b1FLC \u03ba\/\u03bb.<br \/>\n2. \u039f \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03c9\u03bd \u03ad\u03c7\u03b5\u03b9 \u03bb\u03ac\u03b2\u03b5\u03b9 1 \u03ad\u03c9\u03c2 3 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03ba\u03b1\u03c4\u03ac \u03c4\u03bf\u03c5 \u03bc\u03c5\u03b5\u03bb\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2.<br \/>\n3. \u039f \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03c9\u03bd \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03ad\u03c7\u03b5\u03b9 \u03bb\u03ac\u03b2\u03b5\u03b9 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03ad\u03bd\u03b1 \u03c3\u03c7\u03ae\u03bc\u03b1 \u03c0\u03bf\u03c5 \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7.<br \/>\n4. \u039f \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03c9\u03bd \u03c0\u03ad\u03c4\u03c5\u03c7\u03b5 \u03b5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03b7 \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7 [MR] \u03ae \u03ba\u03b1\u03bb\u03cd\u03c4\u03b5\u03c1\u03b7 \u03bc\u03b5 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 1 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03ba\u03b1\u03c4\u03ac \u03c4\u03bf\u03c5 \u03bc\u03c5\u03b5\u03bb\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2.<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 \u03a3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03c9\u03bd \u03c0\u03bf\u03c5 \u03b5\u03bc\u03c6\u03ac\u03bd\u03b9\u03c3\u03b5 \u03b5\u03be\u03ad\u03bb\u03b9\u03be\u03b7 \u03c4\u03b7\u03c2 \u03bd\u03cc\u03c3\u03bf\u03c5 \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7 \u03b4\u03b9\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03c4\u03b7\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03ae \u03b5\u03bd\u03c4\u03cc\u03c2 60 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03b1\u03c0\u03cc\u03c4\u03b7\u03bd \u03c4\u03b5\u03bb\u03b5\u03c5\u03c4\u03b1\u03af\u03b1 \u03b4\u03cc\u03c3\u03b7 \u03b5\u03bd\u03cc\u03c2 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 \u03c0\u03c1\u03c9\u03c4\u03b5\u03b1\u03c3\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2.<br \/>\n\u2022 \u0393\u03b9\u03b1 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03bf\u03bd\u03c4\u03b5\u03c2 \u03c0\u03bf\u03c5 \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03c5\u03bc\u03ad\u03bd\u03c9\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03c3\u03c7\u03ae\u03bc\u03b1 \u03c0\u03bf\u03c5 \u03c0\u03b5\u03c1\u03b9\u03b5\u03af\u03c7\u03b5 \u03b2\u03bf\u03c1\u03c4\u03b5\u03b6\u03bf\u03bc\u03af\u03bc\u03c0\u03b7, \u03b7\u03b2\u03ad\u03bb\u03c4\u03b9\u03c3\u03c4\u03b7 \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7 \u03c0\u03bf\u03c5 \u03b5\u03c0\u03b9\u03c4\u03b5\u03cd\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b4\u03b5\u03bd \u03ae\u03c4\u03b1\u03bd \u03b5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03b7 \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7 MR) \u03ae \u03ba\u03b1\u03bb\u03cd\u03c4\u03b5\u03c1\u03b7 \u03ae \u03bf \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03c9\u03bd \u03b4\u03b9\u03ad\u03ba\u03bf\u03c8\u03b5 \u03c4\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03b2\u03bf\u03c1\u03c4\u03b5\u03b6\u03bf\u03bc\u03af\u03bc\u03c0\u03b7 \u03bb\u03cc\u03b3\u03c9 \u03c4\u03bf\u03be\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2.<br \/>\n\u2022 \u03a3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03c9\u03bd \u03c0\u03bf\u03c5 \u03ad\u03c7\u03b5\u03b9 \u03bb\u03ac\u03b2\u03b5\u03b9 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 CC-92480 \u03ae \u03c0\u03bf\u03bc\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7.<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc \u03a4\u03bc\u03ae\u03bc\u03b1, \u0393\u039d &#8220;\u03a0\u03b1\u03c0\u03b1\u03b3\u03b5\u03c9\u03c1\u03b3\u03af\u03bf\u03c5&#8221;, \u0398\u03b5\u03c3\u03c3\u03b1\u03bb\u03bf\u03bd\u03af\u03ba\u03b7<br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<\/p>\n<hr \/>\n<p><strong>CA057-008 Successor 2: A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)\u00a0<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3 &amp; \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>1. Participant has documented diagnosis of MM and measurable disease, defined as any of the following:<br \/>\ni) M-protein \u2265 0.5 g\/dL by serum protein electrophoresis (sPEP) or<br \/>\nii) M-protein \u2265 200 mg\/24-hour urine collection by urine protein electrophoresis<br \/>\n(uPEP) or,<br \/>\niii) For participants without measurable disease in sPEP or uPEP: sFLC levels &gt;<br \/>\n100 mg\/L (10 mg\/dL) involved light chain and an abnormal \u03ba\/\u03bb FLC ratio.<br \/>\n2. Participant has received at least 1 prior line of anti-myeloma therapy.<br \/>\n(with or without) consolidation, and\/or (with or without) maintenance therapy).<br \/>\n3. Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody.<br \/>\nNote: Patients who were intolerant of an anti-CD38 mAb and received &lt; 2 cycles are still eligible.<br \/>\n4.Participant achieved minimal response (MR) or better to at least 1 prior anti-myeloma therapy.<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393 \u039d &#8220;\u0393. \u03a0\u0391\u03a0\u0391\u039d\u0399\u039a\u039f\u039b\u0391\u039f\u03a5&#8221;, \u0398\u03b5\u03c3\u03c3\u03b1\u03bb\u03bf\u03bd\u03af\u03ba\u03b7, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0399. \u03a3\u03b1\u03ba\u03b5\u03bb\u03bb\u03ac\u03c1\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u0393\u039d \u03a0\u03b1\u03c4\u03c1\u03ce\u03bd, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0391. \u03a3\u03c0\u03c5\u03c1\u03b9\u03b4\u03c9\u03bd\u03af\u03b4\u03b7\u03c2<br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<\/p>\n<hr \/>\n<p><strong>R5458-ONC-2012 PHASE IB STUDY OF REGN5458 (BISPECIFIC ANTI-CD3 AND ANTI-BCMA ANTIBODY) IN COMBINATION WITH OTHER ANTINEOPLASTIC TREATMENTS FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 ECOG \u22641<br \/>\n\u2022 \u03a5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03b9\u03ac\u03b6\u03bf\u03bd\/\u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc \u03c0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03cc\u03bc\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1 \u03bc\u03b5\u03b5\u03be\u03ad\u03bb\u03b9\u03be\u03b7 \u03ad\u03c0\u03b5\u03b9\u03c4\u03b1 \u03b1\u03c0\u03cc:<br \/>\n\u2022 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 3 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03ae<br \/>\n\u2022 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03ba\u03b1\u03b9<br \/>\n\u03b5\u03af\u03c4\u03b5 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03ad\u03ba\u03b8\u03b5\u03c3\u03b7 \u03c3\u03b5 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 1 \u03b1\u03bd\u03c4\u03b9-CD38 \u03b1\u03bd\u03c4\u03af\u03c3\u03c9\u03bc\u03b1, 1 IMiD \u03ba\u03b1\u03b9 1 PI<br \/>\n\u03b5\u03af\u03c4\u03b5 \u03b4\u03b9\u03c0\u03bb\u03ae \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1 \u03c3\u03b5 1 PI \u03ba\u03b1\u03b9 1 IMiD \u03ae \u03c3\u03c4\u03bf\u03bd \u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc 1 PI \u03ba\u03b1\u03b9 1 IMiD<br \/>\n\u2022 \u039a\u03bf\u03cc\u03c1\u03c4\u03b7 1 \u2013 \u03cc\u03c7\u03b9 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03ae \u03bd\u03cc\u03c3\u03bf\u03c2 \u03c3\u03b5 anti-CD38, &gt;6\u03bc\u03ae\u03bd\u03b5\u03c2 \u03ad\u03ba\u03c0\u03bb\u03c5\u03c3\u03b7<br \/>\n\u2022 \u039a\u03bf\u03cc\u03c1\u03c4\u03b7 2 \u2013 \u03cc\u03c7\u03b9 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03ae \u03bd\u03cc\u03c3\u03bf\u03c2 \u03c3\u03b5 carfilzomib, &gt;6\u03bc\u03ae\u03bd\u03b5\u03c2 \u03ad\u03ba\u03c0\u03bb\u03c5\u03c3\u03b7<br \/>\n\u2022 \u039a\u03bf\u03cc\u03c1\u03c4\u03b7 3 \u2013 \u03cc\u03c7\u03b9 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03ae \u03bd\u03cc\u03c3\u03bf\u03c2 \u03c3\u03b5 lenalidomide, &gt;6\u03bc\u03ae\u03bd\u03b5\u03c2 \u03ad\u03ba\u03c0\u03bb\u03c5\u03c3\u03b7<br \/>\n\u2022 \u039a\u03bf\u03cc\u03c1\u03c4\u03b7 4 \u2013 \u03cc\u03c7\u03b9 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03ae \u03bd\u03cc\u03c3\u03bf\u03c2 \u03c3\u03b5 bortezomib, &gt;6\u03bc\u03ae\u03bd\u03b5\u03c2 \u03ad\u03ba\u03c0\u03bb\u03c5\u03c3\u03b7<br \/>\n\u2022 Mpeak&gt;0,5g\/dl \u03ae Upeak&gt;200mg\/24h \u03ae \u03b5\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03b7 \u03b1\u03bb\u03c5\u03c3\u03af\u03b4\u03b1 FLC&gt;10 \u03ba\u03b1\u03b9 abnormal ratio, \u03b3\u03b9\u03b1 IgA \u03a0\u039c \u03b8\u03b1 \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03b5\u03af\u03bd\u03b1\u03b9 \u2265 400 mg\/dL<br \/>\n\u2022 ANC&gt;1000, Hb&gt;8, PLTs&gt;50.000 (\u039a1) \u03ba\u03b1\u03b9 &gt;75000 (\u039a2-\u039a4),<br \/>\n\u2022 EGFR&gt;30ml\/min (\u039a1,\u039a2,\u039a4) \u03ba\u03b1\u03b9 &gt;60 (\u039a3)<br \/>\n\u2022 \u039f\u03bb\u03b9\u03ba\u03ae \u03c7\u03bf\u03bb\u03b5\u03c1\u03c5\u03b8\u03c1\u03af\u03bd\u03b7 \u2264 1,5 x ULN<br \/>\n\u2022 ALT, AST \u2264 2,5 x ULN<\/p>\n<p><strong>K\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03bb\u03ae\u03c8\u03b7 \u03b1\u03bd\u03bf\u03c3\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03b9\u03ce\u03bd \u03c0\u03bf\u03c5 \u03c3\u03c4\u03bf\u03c7\u03b5\u03cd\u03bf\u03c5\u03bd \u03c4\u03bf BCMA, \u03c3\u03c5\u03bc\u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03b1\u03bd\u03bf\u03bc\u03ad\u03bd\u03c9\u03bd\u03c4\u03c9\u03bd \u03b4\u03b9\u03b5\u03b9\u03b4\u03b9\u03ba\u03ce\u03bd \u03b1\u03bd\u03c4\u03b9\u03c3\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd BCMA \u03ba\u03b1\u03b9 \u03c4\u03c9\u03bd \u03b4\u03b9\u03b5\u03b9\u03b4\u03b9\u03ba\u03ce\u03bd \u03bc\u03bf\u03c1\u03af\u03c9\u03bd \u03c3\u03c4\u03c1\u03b1\u03c4\u03bf\u03bb\u03cc\u03b3\u03b7\u03c3\u03b7\u03c2 T \u03ba\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03bd(BiTE), \u03ba\u03b1\u03b8\u03ce\u03c2 \u03ba\u03b1\u03b9 \u03c4\u03c9\u03bd \u03ba\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03bd BCMA CAR \u03a4. \u03a3\u03b7\u03bc\u03b5\u03af\u03c9\u03c3\u03b7: \u03a4\u03b1 \u03c3\u03c5\u03b6\u03b5\u03cd\u03b3\u03bc\u03b1\u03c4\u03b1 \u03b1\u03bd\u03c4\u03b9\u03c3\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2 BCMA-\u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03b4\u03b5\u03bd \u03b5\u03be\u03b1\u03b9\u03c1\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9.<br \/>\n\u2022 \u0395\u03bc\u03b2\u03cc\u03bb\u03b9\u03bf \u03bc\u03b5 \u03b6\u03ce\u03bd\u03c4\u03b5\u03c2 \u03ae \u03b6\u03ce\u03bd\u03c4\u03b5\u03c2 \u03b5\u03be\u03b1\u03c3\u03b8\u03b5\u03bd\u03b7\u03bc\u03ad\u03bd\u03bf\u03c5\u03c2 \u03bf\u03c1\u03b3\u03b1\u03bd\u03b9\u03c3\u03bc\u03bf\u03cd\u03c2 \u03b5\u03bd\u03c4\u03cc\u03c2 28 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03c0\u03c1\u03b9\u03bdc1d1<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<\/p>\n<hr \/>\n<p><strong>GENETECH-GO43227 Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R\/R MM)<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 Serum M-protein \u2265 0.5 g\/dL (\u2265 5 g\/L)<br \/>\n\u2022 Urine M-protein \u2265200 mg\/24 hr<br \/>\n\u2022 Serum free light chain (SFLC) assay: Involved SFLCs \u2265 10 mg\/dL (\u2265 100 mg\/L) and an abnormal SFLC ratio (&lt; 0.26 or &gt; 1.65)<br \/>\n\u2022 Platelet count \u2265 50,000\/mm3<br \/>\n\u2022 ANC \u2265 1000\/mm3<br \/>\n\u2022 Total hemoglobin \u2265 8 g\/dL<br \/>\n\u2022 Creatinine \u22642.0 mg\/dL and creatinine clearance (CrCl) \u226530 mL\/min<br \/>\n\u2022 Patients should have received all available treatment options<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 Prior treatment with cevostamab or another agent targeting FcRH5 \u2219 Inability to comply with protocol-mandated hospitalization and activities restrictions<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<\/p>\n<hr \/>\n<p><strong>GO43980 A Phase Ib, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Patients With Relapsed\/Refractory Multiple Myeloma<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u039f\u03b9 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03ad\u03c7\u03bf\u03c5\u03bd \u03b4\u03b9\u03b1\u03b3\u03bd\u03c9\u03c3\u03c4\u03b5\u03af \u03bc\u03b5 \u03c0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03cc \u03bc\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1 \u03ba\u03b1\u03b9 \u03bd\u03b1 \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 3 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2, \u03c3\u03c5\u03bc\u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03b1\u03bd\u03bf\u03bc\u03ad\u03bd\u03bf\u03c5 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd \u03b5\u03bd\u03cc\u03c2 PI, \u03b5\u03bd\u03cc\u03c2 IMiD \u03ba\u03b1\u03b9 \u03b5\u03bd\u03cc\u03c2 \u03bc\u03bf\u03bd\u03bf\u03ba\u03bb\u03c9\u03bd\u03b9\u03ba\u03bf\u03cd\u03b1\u03bd\u03c4\u03b9\u03c3\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2 \u03ba\u03b1\u03c4\u03ac \u03c4\u03bf\u03c5 CD38. \u039f\u03b9 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bf\u03b9 \u03bf\u03c0\u03bf\u03af\u03bf\u03b9 \u03b4\u03b5\u03bd \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u03bc\u03bf\u03bd\u03bf\u03ba\u03bb\u03c9\u03bd\u03b9\u03ba\u03cc \u03b1\u03bd\u03c4\u03af\u03c3\u03c9\u03bc\u03b1 \u03ba\u03b1\u03c4\u03ac \u03c4\u03bf\u03c5 CD38 \u03bc\u03c0\u03bf\u03c1\u03bf\u03cd\u03bd \u03bd\u03b1 \u03b5\u03bd\u03c4\u03b1\u03c7\u03b8\u03bf\u03cd\u03bd, \u03b5\u03ac\u03bd \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 3 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2.<br \/>\n\u2022 \u03a5\u03c0\u03bf\u03c7\u03ce\u03c1\u03b7\u03c3\u03b7 \u03c4\u03c9\u03bd \u03b1\u03bd\u03b5\u03c0\u03b9\u03b8\u03cd\u03bc\u03b7\u03c4\u03c9\u03bd \u03c3\u03c5\u03bc\u03b2\u03ac\u03bd\u03c4\u03c9\u03bd \u03b1\u03c0\u03cc \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b1\u03bd\u03c4\u03b9\u03ba\u03b1\u03c1\u03ba\u03b9\u03bd\u03b9\u03ba\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c3\u03b5 \u0392\u03b1\u03b8\u03bc\u03bf\u03cd1<br \/>\n\u2022 \u039c\u03b5\u03c4\u03c1\u03ae\u03c3\u03b9\u03bc\u03b7 \u03bd\u03cc\u03c3\u03bf\u03c2 \u03c0\u03bf\u03c5 \u03bf\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03c3\u03cd\u03bc\u03c6\u03c9\u03bd\u03b1 \u03bc\u03b5 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd \u03ad\u03bd\u03b1 \u03b1\u03c0\u03cc \u03c4\u03b1 \u03c0\u03b1\u03c1\u03b1\u03ba\u03ac\u03c4\u03c9:<br \/>\n\u2022 M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u03bf\u03c1\u03bf\u03cd 0,5g\/dL(5g\/L)<br \/>\n\u2022 M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u03bf\u03cd\u03c1\u03c9\u03bd200mg\/24\u03ce\u03c1\u03b5\u03c2<br \/>\n\u2022 \u0395\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03b5\u03c2 SFLC10mg\/dL(100mg\/L)\u03ba\u03b1\u03b9 \u03bc\u03b7 \u03c6\u03c5\u03c3\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03b1\u03bd\u03b1\u03bb\u03bf\u03b3\u03af\u03b1 SFLC(0,26 \u03ae 1,65)<br \/>\n\u2022 AST \u03ba\u03b1\u03b9 ALT3 ULN, \u039f\u03bb\u03b9\u03ba\u03ae \u03c7\u03bf\u03bb\u03b5\u03c1\u03c5\u03b8\u03c1\u03af\u03bd\u03b71,5ULN<br \/>\n\u2022 \u0391\u03c1\u03b9\u03b8\u03bc\u03cc\u03c2 \u03b1\u03b9\u03bc\u03bf\u03c0\u03b5\u03c4\u03b1\u03bb\u03af\u03c9\u03bd 50.000\/mm3, ANC1.000\/mm3, Hb8g\/dL<br \/>\n\u2022 \u039a\u03ac\u03b8\u03b1\u03c1\u03c3\u03b7 \u03ba\u03c1\u03b5\u03b1\u03c4\u03b9\u03bd\u03af\u03bd\u03b7\u03c2 (CrCl)&gt;30mL\/min<br \/>\n\u2022 Ca&lt;11,5mg\/dL<br \/>\n\u2022 \u039b\u03b5\u03c5\u03ba\u03c9\u03bc\u03b1\u03c4\u03af\u03bd\u03b7&gt;2,5g\/dL<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03bf\u03c0\u03bf\u03b9\u03b1\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03b1\u03bd\u03c4\u03b9\u03ba\u03b1\u03c1\u03ba\u03b9\u03bd\u03b9\u03ba\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 (\u03c0.\u03c7.\u03b1\u03ba\u03c4\u03b9\u03bd\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1, \u03c3\u03c5\u03c3\u03c4\u03b7\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1), \u03b5\u03af\u03c4\u03b5 \u03c5\u03c0\u03cc \u03ad\u03c1\u03b5\u03c5\u03bd\u03b1 \u03b5\u03af\u03c4\u03b5 \u03b5\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b7, \u03b5\u03bd\u03c4\u03cc\u03c2 3 \u03b5\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03c9\u03bd \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03ad\u03bd\u03b1\u03c1\u03be\u03b7 \u03c4\u03b7\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03c4\u03b7\u03c2 \u03bc\u03b5\u03bb\u03ad\u03c4\u03b7\u03c2, \u03b5\u03ba\u03c4\u03cc\u03c2 \u03b5\u03ac\u03bd \u03b9\u03c3\u03c7\u03cd\u03b5\u03b9 \u03ad\u03bd\u03b1 \u03b1\u03c0\u03cc \u03c4\u03b1 \u03c0\u03b1\u03c1\u03b1\u03ba\u03ac\u03c4\u03c9 \u03ba\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 \u03ad\u03ba\u03c0\u03bb\u03c5\u03c3\u03b7\u03c2<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<\/p>\n<hr \/>\n<p><strong>A Phase I Study to Evaluate the Pharmacokinetics and Safety of belantamab mafodotin Monotherapy in Participants with Relapsed and\/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3 &amp; \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 Has failed at least 2 prior lines of anti-myeloma treatments, including an immunomodulatory drug (e.g., lenalidomide or pomalidomide) and a proteasome inhibitor (e.g., bortezomib, ixazomib or carfilzomib).<br \/>\n\u2022 Has measurable disease with at least one of the following:<br \/>\nSerum M-protein \u22650.5 g\/dL (\u22655 g\/L)<br \/>\nUrine M-protein \u2265200 mg\/24 h<br \/>\nSerum FLC assay: Involved FLC level \u226510 mg\/dL (\u2265100 mg\/L) and an abnormal serum free light chain ratio (&lt;0.26 or &gt;1.65)<br \/>\n\u2022 CrCl&lt;15 (dialysis or not)<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<\/p>\n<hr \/>\n<p><strong>A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13).<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3 &amp; \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 Has failed at least 2 prior lines of anti-myeloma treatments, including animmunomodulatory drug (e.g., lenalidomide or pomalidomide), and aproteasome inhibitor (e.g., bortezomib, ixazomib or carfilzomib).<br \/>\n\u2022 Has measurable disease with at least 1 of the following:<br \/>\nSerum M-protein \u22650.5 g\/dL (\u22655 g\/L)<br \/>\nUrine M-protein \u2265200 mg\/24h<br \/>\nSerum FLC assay: Involved FLC level \u226510 mg\/dL (\u2265100 mg\/L) and anabnormal serum FLC ratio (&lt;0.26 or&gt;1.65)<br \/>\n\u2022 Group 2 (moderate) Serum bilirubin &gt;1.5 \u2013 3 \u00d7 ULN and any AST<br \/>\n\u2022 eGFR\u226560 mL\/min\/1.73 m2<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<\/p>\n<hr \/>\n<p><strong>54767414LEU2002-EUMELEIA \u039c\u03b9\u03b1 \u0391\u03bd\u03b5\u03b9\u03bb\u03b7\u03bc\u03bc\u03ad\u03bd\u03b7 \u03bc\u03b5 \u03a0\u03c1\u03c9\u03c4\u03bf\u03b2\u03bf\u03c5\u03bb\u03af\u03b1 \u0395\u03c1\u03b5\u03c5\u03bd\u03b7\u03c4\u03ae, \u03a6\u03ac\u03c3\u03b7\u03c2 II, \u03a0\u03bf\u03bb\u03c5\u03ba\u03b5\u03bd\u03c4\u03c1\u03b9\u03ba\u03ae, \u0391\u03bd\u03bf\u03b9\u03ba\u03c4\u03ae\u03c2 \u0395\u03c0\u03b9\u03c3\u03ae\u03bc\u03b1\u03bd\u03c3\u03b7\u03c2, \u0395\u03bd\u03cc\u03c2 \u03a3\u03ba\u03ad\u03bb\u03bf\u03c5\u03c2, \u03a0\u03c1\u03bf\u03bf\u03c0\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u0394\u03bf\u03ba\u03b9\u03bc\u03ae \u03b3\u03b9\u03b1 \u03c4\u03b7\u03bd \u0391\u03be\u03b9\u03bf\u03bb\u03cc\u03b3\u03b7\u03c3\u03b7 \u03c4\u03b7\u03c2 \u0391\u03c0\u03bf\u03c4\u03b5\u03bb\u03b5\u03c3\u03bc\u03b1\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2 \u03ba\u03b1\u03b9 \u03c4\u03b7\u03c2 \u0391\u03c3\u03c6\u03ac\u03bb\u03b5\u03b9\u03b1\u03c2 \u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03c3\u03c3\u03cc\u03bc\u03b5\u03bd\u03c9\u03bd \u03a3\u03c7\u03b7\u03bc\u03ac\u03c4\u03c9\u03bd \u03bc\u03b5 \u0392\u03ac\u03c3\u03b7 \u03c4\u03b7 \u0392\u03bf\u03c1\u03c4\u03b5\u03b6\u03bf\u03bc\u03af\u03bc\u03c0\u03b7 \u03c3\u03b5 \u03a3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc \u03bc\u03b5 \u0394\u03b1\u03c1\u03b1\u03c4\u03bf\u03c5\u03bc\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7 \u0391\u03ba\u03bf\u03bb\u03bf\u03c5\u03b8\u03bf\u03cd\u03bc\u03b5\u03bd\u03b1 \u03b1\u03c0\u03cc \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03a3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7\u03c2 \u03bc\u03b5 \u0394\u03b1\u03c1\u03b1\u03c4\u03bf\u03c5\u03bc\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7 \u03c3\u03c4\u03bf \u03a0\u03bb\u03b1\u03af\u03c3\u03b9\u03bf \u03c4\u03b7\u03c2 \u0391\u03c1\u03c7\u03b9\u03ba\u03ae\u03c2 \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03c4\u03b7\u03c2 \u03a0\u03c1\u03c9\u03c4\u03bf\u03c0\u03b1\u03b8\u03bf\u03cd\u03c2 \u03a0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03b9\u03ba\u03ae\u03c2 \u039b\u03b5\u03c5\u03c7\u03b1\u03b9\u03bc\u03af\u03b1\u03c2: \u039c\u03b9\u03b1 \u0394\u03bf\u03ba\u03b9\u03bc\u03ae \u03c4\u03b7\u03c2 \u0395\u03bb\u03bb\u03b7\u03bd\u03b9\u03ba\u03ae\u03c2 \u039f\u03bc\u03ac\u03b4\u03b1\u03c2 \u039c\u03b5\u03bb\u03ad\u03c4\u03b7\u03c2 \u03c4\u03bf\u03c5 \u03a0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03bf\u03cd \u039c\u03c5\u03b5\u03bb\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 \u0391\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bd\u03b5\u03bf\u03b4\u03b9\u03b1\u03b3\u03bd\u03c9\u03c3\u03b8\u03ad\u03bd\u03c4\u03b5\u03c2 \u03bc\u03b5 \u03c4\u03b5\u03ba\u03bc\u03b7\u03c1\u03b9\u03c9\u03bc\u03ad\u03bd\u03b7 \u03a0\u03a0\u039a\u039b \u03c9\u03c2 \u03bf\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b1 \u03c4\u03c1\u03ad\u03c7\u03bf\u03bd\u03c4\u03b1 \u03b4\u03b9\u03b1\u03b3\u03bd\u03c9\u03c3\u03c4\u03b9\u03ba\u03ac \u03ba\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 IMWG \u03b3\u03b9\u03b1 \u03a0\u039a\u039b \u03ba\u03b1\u03b9 \u03a0\u039c [5,34]:<br \/>\n\u2022 \u03a4\u03b5\u03ba\u03bc\u03b7\u03c1\u03b9\u03c9\u03bc\u03ad\u03bd\u03b7 \u03c0\u03b1\u03c1\u03bf\u03c5\u03c3\u03af\u03b1 \u22655% \u03c0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03bd \u03c3\u03c4\u03bf \u03c0\u03b5\u03c1\u03b9\u03c6\u03b5\u03c1\u03b9\u03ba\u03cc \u03b1\u03af\u03bc\u03b1 (PBPC) \u03ba\u03b1\u03b9\/\u03ae \u22650,5 \u00d7 103 \/\u03bcL \u03c3\u03b5 \u03b1\u03c0\u03cc\u03bb\u03c5\u03c4\u03bf \u03b1\u03c1\u03b9\u03b8\u03bc\u03cc (\u03bc\u03b5 \u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03bf\u03bc\u03b5\u03c4\u03c1\u03af\u03b1 \u03c1\u03bf\u03ae\u03c2)<br \/>\n\u2022 \u226510% \u03ba\u03bb\u03c9\u03bd\u03b9\u03ba\u03ac \u03c0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03cd\u03c4\u03c4\u03b1\u03c1\u03b1 \u03c3\u03c4\u03bf\u03bd \u03bc\u03c5\u03b5\u03bb\u03cc \u03c4\u03c9\u03bd \u03bf\u03c3\u03c4\u03ce\u03bd (BMPC) \u03ae \u03b1\u03c0\u03bf\u03b4\u03b5\u03b4\u03b5\u03b9\u03b3\u03bc\u03ad\u03bd\u03bf \u03bc\u03ad\u03c3\u03c9 \u03b2\u03b9\u03bf\u03c8\u03af\u03b1\u03c2 \u03bf\u03c3\u03c4\u03b9\u03ba\u03cc \u03ae \u03b5\u03be\u03c9\u03bc\u03c5\u03b5\u03bb\u03b9\u03ba\u03cc\u03c0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03cd\u03c4\u03c9\u03bc\u03b1 (EMP)<br \/>\n\u2022 \u0395\u03c0\u03af\u03c0\u03b5\u03b4\u03b1 \u039c-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2 \u03c3\u03c4\u03bf\u03bd \u03bf\u03c1\u03cc: \u2212 \u0393\u03b9\u03b1 IgG \u03a0\u039c: \u22651,0 g\/dL \u03ae \u03b5\u03c0\u03af\u03c0\u03b5\u03b4\u03b1 M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2 \u03c3\u03c4\u03b1 \u03bf\u03cd\u03c1\u03b1 \u2265200 mg\/24\u03c9\u03c1\u03bf \u2212 \u0393\u03b9\u03b1 IgA, IgE \u03ba\u03b1\u03b9 IgM \u03a0\u039c: \u22650,5 g\/dL \u03ae \u03b5\u03c0\u03af\u03c0\u03b5\u03b4\u03b1 M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2 \u03c3\u03c4\u03b1 \u03bf\u03cd\u03c1\u03b1 \u2265200 mg\/ 24\u03c9\u03c1\u03bf \u2212 \u0393\u03b9\u03b1 IgD \u03a0\u039c: \u22650,05 g\/dL \u03ae \u03b5\u03c0\u03af\u03c0\u03b5\u03b4\u03b1 M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2 \u03c3\u03c4\u03b1 \u03bf\u03cd\u03c1\u03b1 \u2265200 mg\/\u00a0\u00a0 24\u03c9\u03c1\u03bf<br \/>\n\u2022 \u03a0\u039c \u03b5\u03bb\u03b1\u03c6\u03c1\u03ce\u03bd \u03b1\u03bb\u03cd\u03c3\u03c9\u03bd \u03c7\u03c9\u03c1\u03af\u03c2 \u03bc\u03b5\u03c4\u03c1\u03ae\u03c3\u03b9\u03bc\u03b7 \u03bd\u03cc\u03c3\u03bf \u03c3\u03c4\u03bf\u03bd \u03bf\u03c1\u03cc \u03ae \u03c3\u03c4\u03b1 \u03bf\u03cd\u03c1\u03b1: \u03b5\u03bb\u03b5\u03cd\u03b8\u03b5\u03c1\u03b5\u03c2 \u03b5\u03bb\u03b1\u03c6\u03c1\u03ad\u03c2 \u03ac\u03bb\u03c5\u03c3\u03bf\u03b9 \u03c3\u03c4\u03bf\u03bd \u03bf\u03c1\u03cc (sFLC) \u226510 mg\/dL (\u03b5\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03b7 \u03b5\u03bb\u03b1\u03c6\u03c1\u03ac \u03ac\u03bb\u03c5\u03c3\u03bf\u03c2) \u03ba\u03b1\u03b9 \u03c0\u03b1\u03b8\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc\u03c2 \u03bb\u03cc\u03b3\u03bf\u03c2 \u03ba\/\u03bb \u03b5\u03bb\u03b5\u03cd\u03b8\u03b5\u03c1\u03c9\u03bd \u03b5\u03bb\u03b1\u03c6\u03c1\u03ce\u03bd \u03b1\u03bb\u03cd\u03c3\u03c9\u03bd \u03c3\u03c4\u03bf\u03bd \u03bf\u03c1\u03cc.<br \/>\n\u2022 \u0391\u03b9\u03bc\u03bf\u03c3\u03c6\u03b1\u03b9\u03c1\u03af\u03bd\u03b7 \u22657,0 g\/dL<br \/>\n\u2022 \u0391\u03c0\u03cc\u03bb\u03c5\u03c4\u03bf\u03c2 \u03b1\u03c1\u03b9\u03b8\u03bc\u03cc\u03c2 \u03bf\u03c5\u03b4\u03b5\u03c4\u03b5\u03c1\u03bf\u03c6\u03af\u03bb\u03c9\u03bd (ANC) \u22651,0 x 109 \/L<br \/>\n\u2022 \u0391\u03c1\u03b9\u03b8\u03bc\u03cc\u03c2 \u03b1\u03b9\u03bc\u03bf\u03c0\u03b5\u03c4\u03b1\u03bb\u03af\u03c9\u03bd \u226550 x 109 \/L<br \/>\n\u2022 \u0395\u03c0\u03b1\u03c1\u03ba\u03ae\u03c2 \u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1 \u03cc\u03c0\u03c9\u03c2 \u03ba\u03b1\u03b8\u03bf\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03b5\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03b7 CrCl \u226520 mL\/min<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 \u0391\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 \u03b4\u03b5\u03c5\u03c4\u03b5\u03c1\u03bf\u03c0\u03b1\u03b8\u03ae \u03a0\u039a\u039b<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d \u039b\u03b1\u03ca\u03ba\u03cc, \u0391\u03b8\u03ae\u03bd\u03b1, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u039c. \u039a\u03c5\u03c1\u03c4\u03c3\u03ce\u03bd\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u039c\u0395\u03a4\u0391\u039e\u0391&#8221;, \u03a0\u03b5\u03b9\u03c1\u03b1\u03b9\u03ac\u03c2, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u039c. \u039a\u03c9\u03c4\u03c3\u03bf\u03c0\u03bf\u03cd\u03bb\u03bf\u03c5<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u03a0\u0393\u039d \u0391\u03bb\u03b5\u03be\u03b1\u03bd\u03b4\u03c1\u03bf\u03cd\u03c0\u03bf\u03bb\u03b7\u03c2, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395\u03bc. \u03a3\u03c0\u03b1\u03bd\u03bf\u03c5\u03b4\u03ac\u03ba\u03b7\u03c2<br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395. \u03a4\u03ad\u03c1\u03c0\u03bf\u03c2<\/p>\n<hr \/>\n<p><strong>ACT16482- isatuximab+ SAR444245 (THOR-707) Substudy 4, SAR444245 is an intravenous (IV) formulation of a pegylated human recombinant IL-2 variant<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3 &amp; \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 Anti-CD38 and anti-BCMA therapy prior exposed participants with RRMM.<br \/>\n\u2022 Participants with relapsed or refractory MM who have received at least 3 prior lines of therapy for MM, including PIs and IMiDs or at least 2 prior lines if at least one of these lines consisted of 2 or more multiagent regimens (eg, Induction regimen with autologous stem cell transplant followed by maintenance).<br \/>\n\u2022 RRMM with measurable disease:<br \/>\n\u2022 Serum M protein \u22650.5 g\/dL measured using serum protein immunoelectrophoresis and\/or<br \/>\n\u2022 Urine M protein \u2265200 mg\/24 hours measured using urine protein immunoelectrophoresis and\/or<br \/>\n\u2022 Serum free light chain (sFLC) MM without measurable M protein in serum or urine per previous criteria (serum Ig free light chain \u226510 mg\/dL and abnormal serum Ig kappa lambda free light chain ratio<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<\/p>\n<hr \/>\n<p><strong>ACT17453 subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone, 1-3 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 \u039c \u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u03bf\u03c1\u03bf\u03cd \u22650,5 g\/dL \u03ae\/\u03ba\u03b1\u03b9 \u2022 \u039c \u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u03bf\u03cd\u03c1\u03c9\u03bd \u2265200 mg\/24 \u03ce\u03c1\u03b5\u03c2 \u03ae\/\u03ba\u03b1\u03b9 \u2022 \u03b5\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03c9\u03bd FLC \u226510 mg\/dL (\u2265100 mg\/L) \u03ba\u03b1\u03b9 \u03bc\u03b7 \u03c6\u03c5\u03c3\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03b1\u03bd\u03b1\u03bb\u03bf\u03b3\u03af\u03b1 FLC \u03bf\u03c1\u03bf\u03cd (1,65).<br \/>\n\u2022 Y\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03b9\u03ac\u03b6\u03bf\u03bd \u03ae\/\u03ba\u03b1\u03b9 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc \u03a0\u039c \u03bc\u03b5 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 1 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03ba\u03b1\u03b9 \u03cc\u03c7\u03b9 \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u03b1\u03c0\u03cc 3 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2.<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 \u03a0\u03c1\u03c9\u03c4\u03bf\u03c0\u03b1\u03b8\u03ad\u03c2 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc \u03a0\u039c (\u03cc\u03c7\u03b9 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd \u03b5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03b7 \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7 (MR) \u03bc\u03b5 \u03bf\u03c0\u03bf\u03b9\u03b1\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7 \u03b4\u03b9\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03c4\u03b7\u03c2 \u03c0\u03bf\u03c1\u03b5\u03af\u03b1\u03c2 \u03c4\u03b7\u03c2 \u03bd\u03cc\u03c3\u03bf\u03c5<br \/>\n\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03b1\u03bd\u03c4\u03b9-CD38:\u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1 \u03c3\u03c4\u03bf \u03b1\u03bd\u03c4\u03b9CD38, \u03bc\u03b5 \u03c0\u03b5\u03c1\u03af\u03bf\u03b4\u03bf \u03ad\u03ba\u03c0\u03bb\u03c5\u03c3\u03b7\u03c2 \u03bc\u03b9\u03ba\u03c1\u03cc\u03c4\u03b5\u03c1\u03b7 \u03b1\u03c0\u03cc 9 \u03bc\u03ae\u03bd\u03b5\u03c2 \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03c0\u03c1\u03ce\u03c4\u03b7 \u03c7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7 \u03c4\u03bf\u03c5 isatuximab, \u039c\u03b7 \u03b1\u03bd\u03bf\u03c7\u03ae<br \/>\n\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03ba\u03b1\u03c1\u03c6\u03b9\u03bb\u03b6\u03bf\u03bc\u03af\u03bc\u03c0\u03b7<br \/>\n\u2022 \u0391\u03bd\u03c4\u03b9-\u03bc\u03c5\u03b5\u03bb\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03b1\u03b3\u03c9\u03b3\u03ae \u03b5\u03bd\u03c4\u03cc\u03c2 14 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03c0\u03c1\u03ce\u03c4\u03b7 \u03c7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7 \u03c4\u03bf\u03c5 isatuximab, \u03c3\u03c5\u03bc\u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03b1\u03bd\u03bf\u03bc\u03ad\u03bd\u03b7\u03c2 \u03c4\u03b7\u03c2 \u03b4\u03b5\u03be\u03b1\u03bc\u03b5\u03b8\u03b1\u03b6\u03cc\u03bd\u03b7\u03c2<br \/>\n\u2022 ECOG&gt;2 \u03ae \u03c0\u03c1\u03bf\u03c3\u03b4\u03cc\u03ba\u03b9\u03bc\u03bf \u03b6\u03c9\u03ae\u03c2 &lt;3 \u03bc\u03ae\u03bd\u03b5\u03c2<br \/>\n\u2022 \u0391\u03b9\u03bc\u03bf\u03c0\u03b5\u03c4\u03ac\u03bb\u03b9\u03b1 &lt;50 x 109\/L \u03b5\u03ac\u03bd &lt;50% \u03c4\u03c9\u03bd \u03b5\u03bc\u03c0\u03cd\u03c1\u03b7\u03bd\u03c9\u03bd \u03ba\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03bd \u03c4\u03bf\u03c5 \u03bc\u03c5\u03b5\u03bb\u03bf\u03cd \u03c4\u03c9\u03bd \u03bf\u03c3\u03c4\u03ce\u03bd (BM) \u03b5\u03af\u03bd\u03b1\u03b9<br \/>\n\u2022 \u03c0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03cd\u03c4\u03c4\u03b1\u03c1\u03b1 \u03ba\u03b1\u03b9 &lt;30.000 \u03ba\u03cd\u03c4\u03c4\u03b1\u03c1\u03b1\/\u00b5L \u03b5\u03ac\u03bd \u226550% \u03c4\u03c9\u03bd \u03b5\u03bc\u03c0\u03cd\u03c1\u03b7\u03bd\u03c9\u03bd \u03ba\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03bd \u03c4\u03bf\u03c5 BM \u03b5\u03af\u03bd\u03b1\u03b9<br \/>\n\u2022 \u03c0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03cd\u03c4\u03c4\u03b1\u03c1\u03b1.<br \/>\n\u2022 \u0391\u03c0\u03cc\u03bb\u03c5\u03c4\u03bf\u03c2 \u03b1\u03c1\u03b9\u03b8\u03bc\u03cc\u03c2 \u03bf\u03c5\u03b4\u03b5\u03c4\u03b5\u03c1\u03cc\u03c6\u03b9\u03bb\u03c9\u03bd (ANC) &lt;1,0 x 109\/L.<br \/>\n\u2022 \u03a1\u03c5\u03b8\u03bc\u03cc\u03c2 \u03c3\u03c0\u03b5\u03b9\u03c1\u03b1\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae\u03c2 \u03b4\u03b9\u03ae\u03b8\u03b7\u03c3\u03b7\u03c2 (GFR) &lt;15 mL\/min\/1,73 m2 [(MDRD)]<br \/>\n\u2022 \u039f\u03bb\u03b9\u03ba\u03ae \u03c7\u03bf\u03bb\u03b5\u03c1\u03c5\u03b8\u03c1\u03af\u03bd\u03b7&gt;1,5 \u00d7 \u03b1\u03bd\u03ce\u03c4\u03b1\u03c4\u03bf \u03c6\u03c5\u03c3\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc \u03cc\u03c1\u03b9\u03bf (ULN)<br \/>\n\u2022 \u039a\u03bb\u03ac\u03c3\u03bc\u03b1 \u03b5\u03be\u03ce\u03b8\u03b7\u03c3\u03b7\u03c2 \u03b1\u03c1\u03b9\u03c3\u03c4\u03b5\u03c1\u03ae\u03c2 \u03ba\u03bf\u03b9\u03bb\u03af\u03b1\u03c2 &lt;40%<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<\/p>\n<hr \/>\n<p><strong>MajesTEC-9 \u03a6\u03ac\u03c3\u03b7 3, TeclistamabMonotherapyversus Pomalidomide, Bortezomib, Dexamethasone (PVd) \u03aeCarfilzomib, Dexamethasone (Kd) \u03c3\u03b5 RRMM1-3 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2\u00a0<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 \u039c \u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u03bf\u03c1\u03bf\u03cd \u22650,5 g\/dL \u03ae\/\u03ba\u03b1\u03b9 \u2022 \u039c \u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u03bf\u03cd\u03c1\u03c9\u03bd \u2265200 mg\/24 \u03ce\u03c1\u03b5\u03c2 \u03ae\/\u03ba\u03b1\u03b9 \u2022 \u03b5\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03c9\u03bd FLC \u226510 mg\/dL (\u2265100 mg\/L) \u03ba\u03b1\u03b9 \u03bc\u03b7 \u03c6\u03c5\u03c3\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03b1\u03bd\u03b1\u03bb\u03bf\u03b3\u03af\u03b1 FLC \u03bf\u03c1\u03bf\u03cd (1,65).<br \/>\n\u2022 Y\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03b9\u03ac\u03b6\u03bf\u03bd \u03ae\/\u03ba\u03b1\u03b9 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc \u03a0\u039c \u03bc\u03b5 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 1 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03ba\u03b1\u03b9 \u03cc\u03c7\u03b9 \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u03b1\u03c0\u03cc 3 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2.<br \/>\n\u2022 \u039f\u03b9 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03b8\u03b1 \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u03c4\u03bf\u03c5 2 \u03ba\u03cd\u03ba\u03bb\u03bf\u03c5\u03c2 \u03bc\u03b5 anti-CD38 \u03ba\u03b1\u03b9 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03b9\u03b4\u03b7<br \/>\n\u2022 PS 0-2<br \/>\n\u2022 \u0397b&gt; 8, PLTs&gt; 75000 (50000), ANC&gt; 1000, eGFR&gt; 30<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 anti-BCMA\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1<br \/>\n\u2022 \u038c\u03c3\u03bf\u03b9 \u03bb\u03ac\u03b2\u03bf\u03c5\u03bd PVd\u03b4\u03b5 \u03b8\u03b1 \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u03c0\u03c1\u03b9\u03bd \u03c0\u03bf\u03bc\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03b9\u03b4\u03b7 \u03ae \u03bd\u03b1 \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03bf\u03af \u03c3\u03b5 \u03b2\u03bf\u03c1\u03c4\u03b5\u03b6\u03bf\u03bc\u03af\u03bc\u03c0\u03b7<br \/>\n\u2022 \u038c\u03c3\u03bf\u03b9 \u03bb\u03ac\u03b2\u03bf\u03c5\u03bd Kd\u03b4\u03b5 \u03b8\u03b1 \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u03c0\u03c1\u03b9\u03bd \u03ba\u03b1\u03c1\u03c6\u03b9\u03bb\u03b6\u03bf\u03bc\u03b9\u03bc\u03c0\u03b7<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393 \u039d &#8220;\u0393. \u03a0\u0391\u03a0\u0391\u039d\u0399\u039a\u039f\u039b\u0391\u039f\u03a5&#8221;, \u0398\u03b5\u03c3\u03c3\u03b1\u03bb\u03bf\u03bd\u03af\u03ba\u03b7<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03a4\u03bc\u03ae\u03bc\u03b1, \u0393 \u039d &#8220;\u0391\u0393\u0399\u039f\u03a3 \u0391\u039d\u0394\u03a1\u0395\u0391\u03a3&#8221;, \u03a0\u03ac\u03c4\u03c1\u03b1<br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<\/p>\n<hr \/>\n<p><strong>COVALENT-101 (On hold)\u2013 \u03a6\u03ac\u03c3\u03b7 1, BMF-219, \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1\u03c2 \u03c4\u03b7\u03c2 \u03bc\u03b5\u03bd\u03af\u03bd\u03b7\u03c2 \u03b1\u03c0\u03cc \u03c4\u03bf \u03c3\u03c4\u03cc\u03bc\u03b1<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 3 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2<br \/>\n\u2022 PS 0-2<br \/>\nCohort 3 only: Must have received at least 3 anti-MM regimens including proteasome inhibitor (e.g., bortezomib or carfilzomib) and immunomodulatory drug (ImiD; e.g., lenalidomide or pomalidomide) therapy.<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<\/p>\n<hr \/>\n<p><strong>MONUMENTAL-3 \u039c\u03b9\u03b1 \u03c4\u03c5\u03c7\u03b1\u03b9\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03b7 \u03bc\u03b5\u03bb\u03ad\u03c4\u03b7 \u03a6\u03ac\u03c3\u03b7\u03c2 3 \u03b3\u03b9\u03b1 \u03c4\u03b7 \u03c3\u03cd\u03b3\u03ba\u03c1\u03b9\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03a5\u0394 \u03c4\u03b1\u03bb\u03ba\u03b5\u03c4\u03b1\u03bc\u03ac\u03bc\u03c0\u03b7\u03c2 \u03c3\u03b5 \u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc \u03bc\u03b5 \u03a5\u0394 \u03b4\u03b1\u03c1\u03b1\u03c4\u03bf\u03c5\u03bc\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7 \u03ba\u03b1\u03b9 \u03c0\u03bf\u03bc\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7 (Tal-DP) \u03ae \u03c4\u03b7\u03c2 \u03a5\u0394 \u03c4\u03b1\u03bb\u03ba\u03b5\u03c4\u03b1\u03bc\u03ac\u03bc\u03c0\u03b7\u03c2 \u03c3\u03b5 \u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc \u03bc\u03b5 \u03a5\u0394 \u03b4\u03b1\u03c1\u03b1\u03c4\u03bf\u03c5\u03bc\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7 (Tal-D) \u03ad\u03bd\u03b1\u03bd\u03c4\u03b9 \u03c4\u03b7\u03c2 \u03a5\u0394 \u03b4\u03b1\u03c1\u03b1\u03c4\u03bf\u03c5\u03bc\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7\u03c2, \u03c0\u03bf\u03bc\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7\u03c2 \u03ba\u03b1\u03b9 \u03b4\u03b5\u03be\u03b1\u03bc\u03b5\u03b8\u03b1\u03b6\u03cc\u03bd\u03b7\u03c2 (DPd) \u03c3\u03b5 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03bf\u03bd\u03c4\u03b5\u03c2 \u03bc\u03b5 \u03c5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03b9\u03ac\u03b6\u03bf\u03bd \u03ae \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc \u03c0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03cc \u03bc\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1 \u03c0\u03bf\u03c5 \u03b5\u03af\u03c7\u03b1\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u2265 1 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u039b\u03ae\u03c8\u03b7 \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 1 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae\u03c2 \u03b1\u03bd\u03c4\u03b9\u03bc\u03c5\u03b5\u03bb\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b5\u03c1\u03b9\u03bb\u03ac\u03bc\u03b2\u03b1\u03bd\u03b5 PI \u03ba\u03b1\u03b9 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7. \u039f\u03b9 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03bf\u03bd\u03c4\u03b5\u03c2 \u03c0\u03bf\u03c5 \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u03bc\u03cc\u03bd\u03bf 1 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae \u03b1\u03bd\u03c4\u03b9\u03bc\u03c5\u03b5\u03bb\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03b8\u03b5\u03c9\u03c1\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03bf\u03af \u03c3\u03c4\u03b7 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7 (\u03b4\u03b7\u03bb. \u03bd\u03b1 \u03ad\u03c7\u03bf\u03c5\u03bd \u03c0\u03b1\u03c1\u03bf\u03c5\u03c3\u03b9\u03ac\u03c3\u03b5\u03b9 \u03b5\u03be\u03b5\u03bb\u03b9\u03c3\u03c3\u03cc\u03bc\u03b5\u03bd\u03b7 \u03bd\u03cc\u03c3\u03bf \u03b2\u03ac\u03c3\u03b5\u03b9 \u03c4\u03c9\u03bd \u03ba\u03c1\u03b9\u03c4\u03b7\u03c1\u03af\u03c9\u03bd IMWG \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7 \u03b4\u03b9\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03c4\u03b7\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03ae \u03b5\u03bd\u03c4\u03cc\u03c2 60 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03bf\u03bb\u03bf\u03ba\u03bb\u03ae\u03c1\u03c9\u03c3\u03b7 \u03c3\u03c7\u03ae\u03bc\u03b1\u03c4\u03bf\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7). \u039f\u03b9 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03bf\u03bd\u03c4\u03b5\u03c2 \u03c0\u03bf\u03c5 \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u2265 2 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03b1\u03bd\u03c4\u03b9\u03bc\u03c5\u03b5\u03bb\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03c0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03b8\u03b5\u03c9\u03c1\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b5\u03ba\u03c4\u03b5\u03b8\u03b5\u03b9\u03bc\u03ad\u03bd\u03bf\u03b9 \u03c3\u03c4\u03b7 \u03bb\u03b5\u03bd\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7<\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0391\u03a0\u039f\u039a\u039b\u0395\u0399\u03a3\u039c\u039f\u03a5<\/strong><\/p>\n<p>\u2022 \u0397 \u03bd\u03cc\u03c3\u03bf\u03c2 \u03b8\u03b5\u03c9\u03c1\u03b5\u03af\u03c4\u03b1\u03b9 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03ae \u03c3\u03b5 \u03bc\u03bf\u03bd\u03bf\u03ba\u03bb\u03c9\u03bd\u03b9\u03ba\u03cc \u03b1\u03bd\u03c4\u03af\u03c3\u03c9\u03bc\u03b1 \u03ad\u03bd\u03b1\u03bd\u03c4\u03b9 \u03c4\u03bf\u03c5 CD38<br \/>\n\u2022 \u03a0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03ae \u03c4\u03b1\u03c5\u03c4\u03cc\u03c7\u03c1\u03bf\u03bd\u03b7 \u03ad\u03ba\u03b8\u03b5\u03c3\u03b7 \u03c3\u03b5 \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b1 \u03b1\u03ba\u03cc\u03bb\u03bf\u03c5\u03b8\u03b1, \u03b5\u03bd\u03c4\u03cc\u03c2 \u03c4\u03bf\u03c5 \u03ba\u03b1\u03b8\u03bf\u03c1\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03c7\u03c1\u03bf\u03bd\u03b9\u03ba\u03bf\u03cd \u03c0\u03bb\u03b1\u03b9\u03c3\u03af\u03bf\u03c5 \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03c4\u03c5\u03c7\u03b1\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7:<br \/>\n\u03b1.\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c0\u03bf\u03c5 \u03c3\u03c4\u03bf\u03c7\u03b5\u03cd\u03b5\u03b9 \u03c4\u03bf GPRC5D<br \/>\n\u03b2.\u039b\u03ae\u03c8\u03b7 \u03c0\u03c1\u03bf\u03b7\u03b3\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03bc\u03b5 \u03c0\u03bf\u03bc\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7<br \/>\n\u03b3.\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03b1\u03bd\u03b1\u03ba\u03b1\u03c4\u03b5\u03cd\u03b8\u03c5\u03bd\u03c3\u03b7\u03c2 \u03a4-\u03bb\u03b5\u03bc\u03c6\u03bf\u03ba\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03bd (\u03b3\u03b9\u03b1 \u03c0\u03b1\u03c1\u03ac\u03b4\u03b5\u03b9\u03b3\u03bc\u03b1, \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03b1\u03bd\u03c4\u03b9\u03c3\u03ce\u03bc\u03b1\u03c4\u03b1 \u03ae BiTE) \u03b5\u03bd\u03c4\u03cc\u03c2 3 \u03bc\u03b7\u03bd\u03ce\u03bd<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0398\u03b5\u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03bf&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u039a\u03b1\u03c4\u03c9\u03b4\u03c1\u03cd\u03c4\u03bf\u03c5<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc \u03a4\u03bc\u03ae\u03bc\u03b1, \u0393\u039d &#8220;\u03a0\u03b1\u03c0\u03b1\u03b3\u03b5\u03c9\u03c1\u03b3\u03af\u03bf\u03c5&#8221;, \u0398\u03b5\u03c3\u03c3\u03b1\u03bb\u03bf\u03bd\u03af\u03ba\u03b7<\/p>\n<hr \/>\n<p><strong>GCT3014-01 &#8211; \u03a6\u03ac\u03c3\u03b7 1\/2 GEN3014 (HexaBody-CD38) \u03c3\u03b5 \u03c5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03b9\u03ac\u03b6o\u03bd \u03ae \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc \u03c0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03cc \u03bc\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1 \u03ba\u03b1\u03b9 \u03ac\u03bb\u03bb\u03b5\u03c2 \u03b1\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ad\u03c2 \u03ba\u03b1\u03ba\u03bf\u03ae\u03b8\u03b5\u03b9\u03b5\u03c2<\/strong><\/p>\n<p><strong>\u039a\u03a1\u0399\u03a4\u0397\u03a1\u0399\u0391 \u0395\u039d\u03a4\u0391\u039e\u0397\u03a3<\/strong><\/p>\n<p>\u2022 PS 0-2<br \/>\n\u2022 CrCl \u226550 mL\/min, Hb \u22658 g\/dL, ANC&gt; 1000, PLTs&gt; 50000<br \/>\n\u2022 Mpeak\u22650.5 g\/dL or Upeak \u2265200 mg\/24 hours or sFLC \u226510 mg\/dL<br \/>\n\u2022 For anti-CD38 mAb-naive RRMM subjects: Subject received at least 3 prior lines of therapy including a PI and an IMiD in any order, or is double refractory to a PI and an IMiD; or subject received \u22652 prior lines of therapy if 1 of those lines included a combination of PI and IMiD.\u00a0\u2192 GEN3014 vs Dara<br \/>\n\u2022 For anti-CD38 mAb-treated RRMM subjects: Subject has received at least 2 prior lines of therapy and must have discontinued daratumumab or isatuximab for at least 4 weeks prior to the first dose of GEN3014. \u2192\u00a0All GEN3014<\/p>\n<p><strong>\u039a\u0395\u039d\u03a4\u03a1\u0391 \u03a0\u039f\u03a5 \u03a3\u03a5\u039c\u039c\u0395\u03a4\u0395\u03a7\u039f\u03a5\u039d<\/strong><\/p>\n<p>\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u039b\u03b5\u03bc\u03c6\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u0393\u039d &#8220;\u039f \u0395\u03c5\u03b1\u03b3\u03b3\u03b5\u03bb\u03b9\u03c3\u03bc\u03cc\u03c2&#8221;, \u0391\u03b8\u03ae\u03bd\u03b1 , \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u03a3.\u0394\u03b5\u03bb\u03ae\u03bc\u03c0\u03b1\u03c3\u03b7<br \/>\n\u2022\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae, \u039d\u03bf\u03ba\u03bf\u03c3\u03bf\u03ba\u03bf\u03bc\u03b5\u03af\u03bf &#8220;\u0391\u03bb\u03b5\u03be\u03ac\u03bd\u03b4\u03c1\u03b1&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03bf\u03c2 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba.\u039c.\u0391 \u0394\u03b7\u03bc\u03cc\u03c0\u03bf\u03c5\u03bb\u03bf\u03c2<br \/>\n\u2022\u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc \u03a4\u03bc\u03ae\u03bc\u03b1, \u03a0\u0393\u039d &#8220;\u0391\u03a7\u0395\u03a0\u0391&#8221;, \u03a5\u03c0\u03b5\u03cd\u03b8\u03c5\u03bd\u03b7 \u0399\u03b1\u03c4\u03c1\u03cc\u03c2 \u03ba. \u0395.\u03a7\u03b1\u03c4\u03b6\u03b7\u03c7\u03b1\u03c1\u03af\u03c3\u03b7<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u039d\u0395\u039f\u0394\u0399\u0391\u0393\u039d\u03a9\u03a3\u0398\u0395\u039d\u03a4\u0395\u03a3 \u0391\u03a3\u0398\u0395\u039d\u0395\u0399\u03a3 \u039c\u0395 \u03a0\u039f\u039b\u039b\u0391\u03a0\u039b\u039f \u039c\u03a5\u0395\u039b\u03a9\u039c\u0391 EMN33-TAURUS Transplant eligible DARAVRD induction-ASCT-2 \u039a\u03cd\u03ba\u03bb\u03bf\u03b9 DARAVRD consolidation \u039d\u03ad\u03b1 \u03b4\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7 \u03bc\u03b5 \u03c3\u03c5\u03bc\u03c0\u03c4\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03cc \u03c0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03cc \u03bc\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1 eGFR &gt; 30ml\/min Mpeak &gt; 0.5 g\/dL,<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[178],"tags":[],"class_list":["post-2772","post","type-post","status-publish","format-standard","hentry","category-active-clinical-studies-en"],"_links":{"self":[{"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/posts\/2772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/comments?post=2772"}],"version-history":[{"count":2,"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/posts\/2772\/revisions"}],"predecessor-version":[{"id":2779,"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/posts\/2772\/revisions\/2779"}],"wp:attachment":[{"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/media?parent=2772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/categories?post=2772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eae.gr\/en\/wp-json\/wp\/v2\/tags?post=2772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}